

A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis

Sinton, Matthew; Meseguer-Ripolles, Jose; Lucendo-Villarin, Baltasar; Wernig-Zorc, Sara; Thomson, John; Carter, Roderick; Lyall, Macrus; Walker, Paul; Thakker, Alpesh; Meehan, Richard; Lavery, Gareth; Morton, Nicholas; Ludwig, Christian; Tennant, Daniel; Hay, David; Drake, Amanda

DOI:

<https://doi.org/10.1016/j.isci.2020.101931>

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Sinton, M, Meseguer-Ripolles, J, Lucendo-Villarin, B, Wernig-Zorc, S, Thomson, J, Carter, R, Lyall, M, Walker, P, Thakker, A, Meehan, R, Lavery, G, Morton, N, Ludwig, C, Tennant, D, Hay, D & Drake, A 2021, 'A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis', *iScience*, vol. 24, no. 1, 101931. <https://doi.org/10.1016/j.isci.2020.101931>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.


Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Article

A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis



Matthew C. Sinton, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, ..., Daniel A. Tennant, David C. Hay, Amanda J. Drake

davehay@talktalk.net (D.C.H.)
mandy.drake@ed.ac.uk
(A.J.D.)

HIGHLIGHTS
LPO-exposed hPSC-derived hepatocyte-like cells resemble human hepatic steatosis

Steatosis is associated with decreased mitochondrial maximal respiration

Purine nucleotide cycle activity increases in steatotic hepatocytes

Excess fumarate production is associated with induction of macrovesicular steatosis

Sinton et al., iScience 24, 101931
January 22, 2021 © 2020 The Author(s).
<https://doi.org/10.1016/j.isci.2020.101931>



Article

A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis

Matthew C. Sinton,¹ Jose Meseguer-Ripolles,² Baltasar Lucendo-Villarin,² Sara Wernig-Zorc,³ John P. Thomson,⁴ Roderick N. Carter,¹ Marcus J. Lyall,¹ Paul D. Walker,⁵ Alpesh Thakker,⁵ Richard R. Meehan,⁴ Gareth G. Lavery,⁵ Nicholas M. Morton,¹ Christian Ludwig,⁵ Daniel A. Tennant,⁵ David C. Hay,^{2,6,*} and Amanda J. Drake^{1,*}

SUMMARY

Nonalcoholic fatty liver disease (NAFLD) is currently the most prevalent form of liver disease worldwide. This term encompasses a spectrum of pathologies, from benign hepatic steatosis to non-alcoholic steatohepatitis, which have, to date, been challenging to model in the laboratory setting. Here, we present a human pluripotent stem cell (hPSC)-derived model of hepatic steatosis, which overcomes inherent challenges of current models and provides insights into the metabolic rewiring associated with steatosis. Following induction of macrovesicular steatosis in hepatocyte-like cells using lactate, pyruvate, and octanoate (LPO), respirometry and transcriptomic analyses revealed compromised electron transport chain activity. ¹³C isotopic tracing studies revealed enhanced TCA cycle anaplerosis, with concomitant development of a compensatory purine nucleotide cycle shunt leading to excess generation of fumarate. This model of hepatic steatosis is reproducible, scalable, and overcomes the challenges of studying mitochondrial metabolism in currently available models.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common form of hepatic disease and is strongly associated with obesity and type 2 diabetes (WHO, 2006). In the earliest stage of NAFLD, triglyceride (TG) accumulation in hepatocytes leads to the development of hepatic steatosis (Valenti et al., 2016). This is characterized by the development of macrovesicular steatosis, with TG storage in large lipid droplets (Wang and Yu, 2016). Although steatosis is largely benign, it can progress to nonalcoholic steatohepatitis (NASH), which, in turn, increases the risk of developing cirrhosis and hepatocellular carcinoma (Asrih and Jornayvaz, 2015). However, the mechanism(s) underlying this progression have yet to be determined. At present, there are no specific therapeutics available to reverse or treat NAFLD, and the only effective intervention is through the reduction of obesity through diet and exercise or following bariatric surgery (Laursen et al., 2019).

In order to understand the pathophysiology of the NAFLD disease spectrum, studies have been undertaken in rodent models, *in vitro* culture systems, and human liver biopsy samples. Dietary intervention or genetic manipulation leading to the development of obesity and/or hepatic steatosis in rodents often fails to fully recapitulate the NAFLD phenotype. For example, although the leptin-deficient Ob/Ob mouse develops extreme obesity and metabolic abnormalities, the profound abnormalities in circulating leptin mean that this model is not representative of human disease in the general population (Anstee and Goldin, 2006; Rotundo et al., 2018). Likewise, dietary interventions mimic specific stages of NAFLD, such as steatosis or inflammation, but do not reflect the disease progression that occurs in humans (Oligschlaeger and Shiri-Sverdlov, 2020). A common dietary intervention is the methyl-donor-deficient (MDD) diet, which recapitulates the inflammatory responses associated with NASH but not the other elements of the metabolic syndrome (Lyall et al., 2017; Rinella and Green, 2004). *In vitro* approaches commonly utilize immortalized cell lines derived from hepatocellular carcinoma; however, malignant transformation is known to induce profound changes in metabolic phenotype (Huang et al., 2013; Pavlova and Thompson, 2016), limiting their utility for modeling NAFLD metabolism. Using whole liver tissue from rodent models or humans to study

¹University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

²Centre for Regenerative Medicine, University of Edinburgh, Institute for Regeneration and Repair, Edinburgh BioQuarter, 5 Little France Crescent, Edinburgh, EH16 4UU, UK

³Department of Biochemistry, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany

⁴Human Genetics Unit, University of Edinburgh, MRC Institute for Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4, 2XU, UK

⁵Institute of Metabolism and Systems Research, IBR Tower, College of Medical and Dental Sciences, Edgbaston, University of Birmingham, Birmingham, B15 2TT, UK

⁶Lead contact

*Correspondence: davehay@talktalk.net (D.C.H.), mandy.drake@ed.ac.uk (A.J.D.)

<https://doi.org/10.1016/j.isci.2020.101931>



metabolism in distinct cell populations necessitates disaggregation and sorting, a process that induces oxidative stress, potentially confounding analyses (Llufrio et al., 2018). Analysis of primary cells may also be confounded by the cell sorting process (Llufrio et al., 2018).

In terms of mechanisms, studies in animal models and humans have shown that NAFLD is associated with mitochondrial dysfunction including altered electron transport chain (ETC) activity (Koliaki et al., 2015; Rector et al., 2010), altered tricarboxylic acid (TCA) cycle activity and anaplerosis (Satapati et al., 2012; Sunny et al., 2011), induced oxidative metabolism, with a proportional increase in oxidative stress (Satapati et al., 2015) and changes in mitochondrial respiration (Koliaki et al., 2015). In these studies, the presence of multiple cell types in tissue samples may confound the results, and this is further complicated by the changes in cell proportions that may occur in disease states.

Here, we present a human-relevant model of hepatic steatosis that can be used for high-resolution analysis of metabolic function and that may provide novel insights into human NAFLD. We hypothesized that nutrient excess in NAFLD leads to increases in ETC activity due to increased availability of respiratory substrates. We aimed to determine the impact of lipid accumulation on mitochondrial respiration specifically in hepatocytes, to avoid the confounding effects associated with bulk tissue analysis.

RESULTS

Lactate, pyruvate, and octanoate treatment induces macrovesicular steatosis in hepatocyte-like cells

We and others have previously reported that the high-energy substrate cocktail LPO promotes intracellular lipid accumulation in pluripotent stem-cell-derived hepatocyte-like cells (HLCs) (Lyll et al., 2018) (schematic of this process is shown in Figure 1A) and human hepatocyte or hepatoblastoma cell lines (Gilchrist et al., 2010; Lockman et al., 2012, 2016). However, it was not known whether LPO promotes lipid droplet biogenesis or increased accumulation of lipids within existing droplets. Stem-cell-derived HLCs were differentiated and characterized by measuring mRNA levels of a marker of pluripotency (NANOG) and markers of hepatocytes (Albumin; ALB and hepatocyte nuclear factor-4-alpha; HNF4A) (Wang et al., 2017) (Figure 1B). CYP3A4 activity was present in control HLCs and those challenged with LPO, demonstrating that they retained hepatocyte function (Figure 1C). Analysis of gene expression using RT-qPCR showed increased expression of transcripts that are typically associated with intracellular lipid droplet membranes: perilipin 2 (PLIN2), PLIN4, and PLIN5, suggesting an increase in lipid droplet size (Figures 1D and 1F). This was supported by analysis of lipid accumulation using high content imaging, which demonstrated that 48 h of LPO exposure was not associated with a change in the number of intracellular lipid droplets (Figure 1G) but led to a ~2-fold increase in their size (Figure 1H), consistent with the development of macrovesicular steatosis.

LPO treatment induces intracellular lipid accumulation and transcriptomic alterations in key mitochondrial respiratory pathways

Induction of steatosis in HLCs was associated with widespread transcriptomic changes (Figure 2A). Differential gene expression analysis identified 853 downregulated and 826 upregulated genes (\log_2 fold change cut-off >1.5) in LPO exposed cells compared with controls. A selection of candidate genes was validated by RT-qPCR (Figure S1), based on genes that we previously found to be dysregulated in association with steatosis (Lyll et al., 2018). RNA-seq analysis revealed altered expression of a number of genes previously described as having functional roles in the progression of NAFLD, including PLIN2, PPARGC1A, CYP7A1, and HMGCS2 (Figure 2B). Mapping genes with a \log_2 fold change >1.5 to the KEGG pathway database identified a number of enriched pathways (Figures 2C and 1D), including those related to steroid hormone biosynthesis (18 genes) and ascorbate and aldarate metabolism (7 genes) (Table S4). There was extensive downregulation of the histone structural units H1, H2A/B, H3, and H4 and UDP-glucuronosyltransferases, which were enriched in multiple pathways. Specifically comparing transcriptomic data with the KEGG terms "TCA cycle" and "oxidative phosphorylation" revealed marked gene expression changes within these pathways (Figures 2E and 2F) including in the majority of genes encoding enzymes that catalyze metabolite interconversion (Table S5). Analysis of the oxidative phosphorylation pathway revealed an overall downregulation of transcription of genes encoding components of respiratory complexes I (ND1, ND2, ND4L, NDUFS2, NDUFV1, NDUFA10, NDUFB2, NDUFA2, NDUFB10) and IV (COX1, COX411, COX8A, COX6B1), as well as ATP synthase (ATP6V1A, ATP5MF, ATP6V0D1, ATP6V1E1, ATP6, APT5MC2, ATP5MC1) (Table S6).




Figure 1. LPO treatment induces development of macrovesicular lipid droplets, similar to benign steatosis in humans

(A) Schematic overview showing differentiation process and induction of lipid accumulation.

(B) H9 hPSCs differentiate to HLCs, losing pluripotency as shown by diminished expression of the pluripotency marker NANOG during the differentiation process. Concomitantly, these cells begin expressing the hepatocyte markers albumin (ALB) and hepatocyte nuclear factor-4-alpha (HNF4A) (n = 3 biological replicates/group).

(C) Differentiated HLCs display robust CYP3A4 activity, which is not diminished following challenge with LPO.

(D–F) Perilipin 2 (PLIN2), PLIN4, and PLIN5 expression increases in response to LPO treatment (n = 3 biological replicates per group).

(G) Number of lipid droplets do not increase,

(H) But intracellular lipid droplets increase in size (n = 32 biological replicates/group). Data were analyzed using two-tailed Student t test and expressed as mean \pm SD, * $p < 0.05$, **** $p < 0.0001$.




Figure 2. Continued

(E–F) Analysis of KEGG TCA cycle and oxidative phosphorylation pathways reveals extensive disruption of expression of key genes. Data in (A) were analyzed using a two-tailed Student's t test. Data in (B) were analyzed by two-way ANOVA with Sidak post-hoc testing. $n = 3$ biological replicates per group. Data are expressed as mean \pm SD.

Macrovesicular steatosis in hepatocytes is associated with electron transport chain dysfunction

It has been suggested that NAFLD-associated macrovesicular steatosis results in impairment of mitochondrial respiration (Koliaki et al., 2015), and we therefore proceeded to analyze this in steatotic HLCs (Figure 3A). Basal oxygen consumption rate (OCR), representing combined mitochondrial and non-mitochondrial oxygen consumption, was unchanged following LPO exposure (Figure 3B). In addition, oligomycin A, a complex V inhibitor decreased OCR equally effectively in control and treatment group. Firstly, this indicated that there were no changes in ATP-linked respiration in response to macrovesicular steatosis (Figure 3C). Secondly, when comparing oligomycin-A-induced alterations in OCR with those following addition of rotenone/antimycin A, we could detect no changes in proton leak between groups (Figure 3D). The addition of the ETC uncoupler FCCP revealed a decrease in maximal respiration in the steatotic HLCs, suggesting mild ETC dysfunction (Figure 3E). Using OCR measurements following FCCP treatment, and comparing with the basal OCR, we calculated that there was a decrease in reserve capacity in the LPO-treated cells, compared with controls (Figure 3F). Subsequently, complex I and III were targeted with rotenone/antimycin A, to completely inhibit oxidative phosphorylation, which reduced OCR to a similar level in both groups, suggesting no difference in non-mitochondrial sources of OCR between the control and steatotic HLCs.

Induction of macrovesicular steatosis is not associated with altered mitochondrial number or mitochondrial integrity

We wanted to analyze whether changes in ETC function, as demonstrated by decreased cellular maximal respiration and reserve capacity, were due to altered numbers of mitochondria. Because these were the only respiratory measurements to change, we hypothesized that this was not the case. To test this, we used a high-content microscopy-based approach to measure intracellular mitochondrial fluorescence and observed no changes following exposure to LPO (Figure 3G), indicating no change in quantity. We then measured protein levels of succinate dehydrogenase subunit A (SDHA) and pyruvate dehydrogenase (PDH) $\alpha 1$ and $\alpha 2$ subunits (Figure 3H; representative blot Figure S2), which localize to the mitochondria. Protein levels of SDHA and PDH did not change in response to intracellular lipid accumulation. Furthermore, there were no changes in mitochondrial or nuclear DNA (Figure S3) and no change in the ratio of nuclear to mitochondrial DNA (Figure 3I), suggesting that mitochondrial number is not altered by LPO-induced macrovesicular steatosis. To analyze whether the observed changes in OCR could be due to diminished mitochondrial integrity rather than ETC dysfunction, we measured citrate synthase (CS) activity. This has previously been described as a measure of mitochondrial integrity (Boutagy et al., 2015; Short et al., 2005). Our findings suggest that LPO treatment has no marked impact on CS activity (Figure 3J), suggesting that mitochondria remain intact following intracellular lipid accumulation. Taken together, these data demonstrate that mitochondrial number was not altered in response to macrovesicular steatosis. This suggests that the altered respiratory complex activity may arise due to reactive oxygen species (ROS)-mediated dysfunction, rather than changes in protein content, although this requires further investigation.

Induction of an NAFLD-like phenotype in HLCs is associated with increased pyruvate carboxylase activity

To investigate TCA cycle dynamics in HLCs, lactate in the LPO cocktail was replaced with $^{13}\text{C}_3$ -lactate. Lactate can enter the TCA cycle via mitochondrial pyruvate metabolism, through either pyruvate carboxylase (PC) or pyruvate dehydrogenase (PDH). Alternatively, pyruvate can be transported into the cytosol and used in gluconeogenesis (Figure 4A). LPO exposure was associated with increases in steady state levels of pyruvate, aspartate, and citrate, but there were no changes in metabolites associated with the gluconeogenesis pathway (Figure 4B). Although pyruvate was added as part of the LPO cocktail, increased pyruvate generation also occurred as a result of increased lactate dehydrogenase activity (Figure 4C). Although we were unable to directly measure oxaloacetate levels, we used aspartate as a surrogate and found increased $m+3$ labeling, demonstrating direct synthesis of aspartate from pyruvate (Figure 4D). Furthermore, isotopomer labeling of citrate indicated increased incorporation from pyruvate-derived oxaloacetate and decreased conversion of labeled acetyl-CoA by PDH (Figure 4E). An alternative pathway for pyruvate is




Figure 3. LPO treatment results in decreased mitochondrial maximal respiration and reserve capacity, suggestive of respiratory complex impairment.

HLCs were injected sequentially from ports A–C with 4 μM oligomycin, 0.5–1 μM FCCP, and 1 μM antimycin combined with 200 nM rotenone. (A) Raw trace of OCR comparing cells with or without LPO treatment; (B) basal respiration (C) ATP-linked respiration and (D) proton leak were unchanged in LPO-treated HLCs. In contrast, maximal respiration (E) and reserve capacity (F) were both diminished following LPO treatment ($n = 18$ and 16 biological replicates in the control and treatment group, respectively, from two plates). (G) High-content microscopy revealed no changes in fluorescence of mitochondrial content in response to treatment ($n = 4$ and 6 biological replicates in the control and treatment group, respectively). Representative images of mitochondrial content in control and LPO-treated groups 10x magnification. Blue staining = NucBlue, red staining = MitoTracker Deep Red. Scale bar: 25 μm (H). There were no changes in abundance of the mitochondrial proteins succinate dehydrogenase subunit (SDHA) or pyruvate dehydrogenase $\alpha 1$ and $\alpha 2$ subunits (PDH) ($n = 6$ biological replicates/group). (I) There were no significant changes in the ratio of mitochondrial to genomic DNA, when comparing mitochondrial region 2 (MT2); mitochondrial region 3 (MT3); or genomic region beta-globin (HBB), indicating no alterations in the quantity of mitochondria in response to treatment ($n = 4$ biological replicates/group). Levels of citrate synthase activity appears unaltered by LPO treatment ($n = 3$ biological replicates/group). Data were analyzed using two-tailed Student t test for parametric data, or Mann-Whitney U test (D, I) for non-parametric data, and expressed as mean \pm SD.




Figure 4. Macrovesicular steatosis is associated with increased PC activity, leading to preferential anaplerosis of pyruvate into the TCA cycle (A) Schematic outlining conversion of lactate to pyruvate and routes by which this can be converted. Black circles denote carbon atoms. (B) Steady state measurements of pyruvate and metabolites that pyruvate can be converted into. Isotopomer labeling patterns of pyruvate (C), aspartate (D), and citrate (E) show anaplerosis into the TCA cycle. There is minimal conversion of pyruvate to alanine (F–G), but increased flux of the m+2 isotopomer through metabolites related to gluconeogenesis, with sustained conversion to 3-PG, serine, and glycine (H–K). For NMR data, labels are: 1 = ^{13}C labeling; 0 = no ^{13}C labeling. All GC-MS data consisted of 10 biological replicates and 2 technical replicates. Isotopomer data were calculated by multiplying MID (multiple ion detection) by normalized total ion count. For NMR data (G and K) $n = 4$ biological replicates/group. Data were analyzed by two-way ANOVA with Sidak post-hoc testing, or (I–J) two-tailed Student's *t* test. Data are expressed as mean \pm SD.

conversion to alanine, and although there were no changes in steady state alanine levels, there were moderate, but significant, changes in the incorporation of ^{13}C (Figure 4F), indicating overall transamination of pyruvate toward alanine. Despite there being no increase in steady state levels of gluconeogenesis-associated metabolites, the increased m+2 labeling of 3-PG (Figure 4G), serine (Figure 4H), and glycine (Figure 4I) suggests increased flux through the gluconeogenesis pathway.

Steatosis in HLCs is associated with increased TCA cycle anaplerosis

Isotopic labeling of TCA metabolites can produce a number of different isotopomers, depending on the directionality of metabolite synthesis (Figure 5A). In steatotic HLCs, we observed increases in steady state




Figure 5. Macrovesicular steatosis in HLCs results in truncation of the TCA cycle, inhibiting conversion of succinate to fumarate.

Paradoxically, this is associated with increased accumulation of fumarate.

(A) Schematic outlining the TCA cycle and possible ^{13}C labeled isotopomers from a single cycle.

(B) Steady state measurements of TCA cycle-associated metabolites that could be measured by GC-MS.

(C) PC-derived αKG is unchanged in the presence of steatosis, and PDH-derived αKG is reduced.

(D–E) Labeling patterns of αKG are not due to increased cataplerosis through glutamate, as both PC- and PDH-derived glutamate are reduced in response to steatosis.

(F) Furthermore, reduced ^{13}C labeling of succinate indicates inefficient conversion from αKG .

(G–H) Despite reduced labeling of succinate, both fumarate and malate show increased PC-derived label incorporation.

(I) Proposed model of preferential anaplerosis of pyruvate into the TCA cycle, with concomitant truncation, preventing conversion of succinate to fumarate. For NMR data, labels are: 1 = ^{13}C labeling; 0 = no ^{13}C labeling. All GC-MS data consisted of 10 biological replicates and 2 technical replicates. Isotopomer data were calculated by multiplying MID (multiple ion detection) by normalized total ion count. For NMR data (E) $n = 4$ biological replicates/group. Data were analyzed by two-way ANOVA with Sidak post-hoc testing and are expressed as mean \pm SD.

levels of the TCA cycle metabolites αKG , fumarate, and malate (Figure 5B). In contrast, there were no changes in the steady state levels of succinate and no evidence for increased metabolism of glutamate. To further analyze alterations in TCA cycle dynamics we measured ^{13}C incorporation into metabolites. Although there was increased ^{13}C incorporation into PC-derived citrate (Figure 4E), this was not the case for αKG (Figure 5C). The decreased levels of ^{13}C incorporation into glutamate suggests that this does not result from increased cataplerosis through glutamate (Figure 5D). The increased expression of OGDHL and decreased expression of SUCG1 (Table S5) suggest that steatosis may be associated with

metabolic reprogramming within the mitochondrial matrix supported by altered protein synthesis. Although decreased incorporation of ^{13}C into succinate was observed (Figure 5E), a parallel increase in ^{13}C incorporation into fumarate, malate, and aspartate was also apparent (Figures 5F and 5G). Because the overall directionality of the malate dehydrogenase and fumarate hydratase reactions can vary depending on the metabolic environment (Dasika et al., 2015; Tyrakis et al., 2017), increased incorporation of ^{13}C into both malate and fumarate indicate increased overall flux of carbons into these metabolites from the oxaloacetate pool. Taken together, this suggests dysregulated TCA cycle flux in steatotic cells, which may be associated with changes in SDH activity (Figure 5H). The increased incorporation of ^{13}C into oxaloacetate (using aspartate as a surrogate) demonstrates increased PC activity, driving the conversion of pyruvate to oxaloacetate and suggests possible disruption of associated metabolic cycles, including the malate-aspartate shuttle (MAS) and the purine nucleotide cycle (PNC).

Increased PNC and MAS activity drives NAFLD-associated fumarate accumulation

Next, we wanted to determine the source of fumarate accumulation in steatotic HLCs. Transcriptomic analysis identified dysregulation of multiple genes associated with the MAS (Figure 6A) and PNC (Figure 6B), indicating that these pathways may be involved in fumarate accumulation. To investigate this further, HLCs incubated with $^{13}\text{C}_3$ -lactate-labeled LPO were co-incubated with either 5-Aminoimidazole-4-carboxamide-1- β -D-ribofuranosyl 5'-monophosphate (AICAR) or O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOA) to inhibit the PNC or MAS, respectively. Addition of AICAR increased only the steady state levels of αKG , and neither AICAR nor AOA had a significant impact on the synthesis of pyruvate, citrate, succinate, or malate (Figure 6C). However, both inhibitors significantly reduced steady state levels of fumarate and aspartate. Although addition of AICAR did not impact on the synthesis of PDH-derived citrate (Figure 6D), it did result in increased accumulation of PDH-derived ^{13}C in αKG (Figure 6E), suggesting impaired conversion to succinyl-CoA or increased anaplerosis from glutamate. AICAR was also able to partially restore the effects of steatosis on succinate levels (Figure 6F), resulting in small but significant increases in PC- and PDH-derived isotopomers. The most profound effect of AICAR was on fumarate, with each isotopomer reduced to levels below those observed in the control group (Figure 6G), suggesting that in steatotic HLCs, fumarate accumulation is primarily driven by the PNC. Following AOA treatment, we observed a moderate decrease in PC-derived ^{13}C incorporation into fumarate, demonstrating a small contribution from the MAS. AICAR had a moderate impact on incorporation of PC-derived incorporation of ^{13}C into malate, whereas AOA impacted on both PC- and PDH-derived ^{13}C incorporation, suggesting limited contribution of the MAS and PNC to malate accumulation (Figure 6H). Both AICAR and AOA reduced incorporation of ^{13}C into aspartate (Figure 6I). These data show that the metabolic consequences of LPO treatment, likely driven by increased TCA cycle anaplerosis through OAA, include an increase in both MAS and PNC activity (Figure 6J).

Inhibition of fumarate accumulation inhibits lipid droplet hypertrophy in LPO-treated HLCs

To determine whether manipulation of fumarate levels affected the development of macrovesicular steatosis, we performed HCA microscopy on HLCs. Cells were treated with LPO in the presence or absence of AICAR. Cells that received AICAR did not develop macrovesicular steatosis (Figure 6K). These results were corroborated by the addition of exogenous fumarate to steatotic HLCs treated with AICAR, which resulted in the development of larger lipid droplets.

Fumarate accumulation is not associated with widescale alterations of 5hmC in protein-coding regions in steatotic HLCs

One potential consequence of fumarate accumulation in steatotic HLCs is inhibition of αKG -dependent dioxygenase enzyme activity. Given our previous data showing altered 5hmC in a mouse model of NAFLD and the potential importance of the TET enzymes in hepatocellular carcinoma (Lyll et al., 2020; Thomson et al., 2016), we used a DIP-seq approach to measure changes in 5hmC across the genome. Within each group, samples were highly correlated, suggesting that the 5hmC patterns are stable between replicate samples (Figure 7A). We identified 3,294 differentially hydroxymethylated regions (DHRs) between LPO exposed and control cells (>2-fold change, see methods), with the majority of changes located in intragenic or intronic regions (Figure 7B). 5hmC in gene body regions may functionally relate to mRNA transcription (Thomson et al., 2016), and we therefore generated heatmaps representing mean changes across the gene body, with cluster 1 showing subtle increases in 5hmC within the TSS region (Figure 7C). Analysis of genic 5hmC patterns revealed that a number of promoter regions displayed changes in 5hmC levels following LPO exposure (Figure 7D). Integration of DHR and RNA-seq data for promoter regions upstream of the




Figure 6. In the presence of TCA cycle truncation, the purine nucleotide cycle and malate-aspartate shuttle fuel fumarate accumulation

(A and B) Transcriptomic analysis showed increased expression of malate-aspartate shuttle (MAS) and purine nucleotide cycle (PNC) transcripts, indicating perturbed activity.

(C) Inhibition of the PNC and MAS reversed steatosis-induced accumulation of fumarate and aspartate but not malate.

(D–G) (D) PNC inhibition moderately impacted PC-derived citrate ^{13}C labeling but not (E) α KG or (F) succinate. (G) In contrast, PNC inhibition profoundly reduced incorporation of ^{13}C into fumarate. MAS inhibition also limited PC-derived fumarate accumulation, but to a lesser extent.

(H) PNC and MAS expression also inhibited generation of PC-derived malate but to a much smaller extent than fumarate.

Figure 6. Continued

(I) PNC and MAS inhibition also resulted in a significant reduction in the generation of PC-derived aspartate.

(J) Schematic outlining of the proposed pathways by which fumarate accumulation occurs in response to steatosis.

(K) Inhibition of fumarate through the PNC reduced LPO-induced macrovesicular steatosis, which was partially restored through addition of exogenous monomethyl fumarate. For NMR data, labels are: 1 = ^{13}C labeling; 0 = no ^{13}C labeling. AICAR = PNC inhibitor; AOA = MAS inhibitor. All control and LPO group GC-MS data consisted of 10 biological replicates and 2 technical replicates, as shown in Figure 3. GC-MS LPO + AICAR and LPO + AOA groups consisted of six biological replicates/group. Isotopomer data were calculated by multiplying MID by normalized total ion count. For lipid droplet analysis (K), the LPO group is as shown in Figure 1. For the LPO + AICAR and the LPO + AICAR + Fumarate group, $n = 31$ and 28 biological replicates/group, respectively. Data were analyzed by two-way ANOVA with Sidak post-hoc testing and are expressed as mean \pm SD.

transcriptional start site revealed 12 promoter regions with differential enrichment of 5hmC (>2-fold) and where mRNA expression was altered >0.5-fold. Linear regression of these regions identified a moderate but significant negative relationship between 5hmC enrichment and mRNA expression (Figure S4; Table S7). Of these genes 7 (EPHX3, ERO1B, CSGALNACT1, DOC2A, COL6A1, CASP1 and TMEM88) were previously shown to be dysregulated in the pathogenesis of NAFLD or progression to cirrhosis (Atanasovska et al., 2017; Cazanave et al., 2017; Parafati et al., 2018; Revall et al., 2013; Wilson and Kumar, 2018). Conversely, to our knowledge, there are no described associations between NAFLD and the remaining genes in this list (DDN, OGFRL1, OCIAD2, ABAT, CCDC150). Our findings may indicate a role for 5hmC in the regulation of these genes in NAFLD pathogenesis.

DISCUSSION

NAFLD is a challenging disease to study in humans. This is due to the difficulty of obtaining tissues that are not compromised by confounding conditions, making high-resolution analysis of transcriptional and metabolic rewiring challenging. In this study we sought to explore the utility of a human-HLC-based model for the study of transcriptomic, epigenomic, and metabolomic dysfunction associated with hepatic steatosis.

Using a combination of high content microscopy and gene expression analyses, we showed that treatment of HLCs with LPO induces intracellular lipid accumulation, recapitulating the macrovesicular steatosis observed in NAFLD (Figure 1G). This was in parallel with changes in the expression of genes associated with lipid droplet size (Figures 1D–1F) and is in agreement with findings from human studies (Fujii et al., 2009; Sahini and Borlak, 2016).

The disruption of the expression of genes in multiple pathways related to metabolism confirms the findings of a number of previous studies in humans and mice (Collison et al., 2009; Hardwick et al., 2013; Kolwankar et al., 2007; Liu et al., 2016; Nikolaou et al., 2019; Schiöth et al., 2016; Suppli et al., 2019; Yamaguchi and Murata, 2013). Consistent with the altered expression of multiple subunits of respiratory complexes I, IV, and ATPase, respirometry-based analyses revealed decreased maximal mitochondrial respiration and spare capacity (Figures 3E and 3F). Previous data suggest that NAFLD associates with inhibition of respiratory activity in complexes I–III in hepatocytes (Koliaki et al., 2015). Our transcriptomic and metabolomic data suggest that this inhibition most likely occurs in complexes I and II. In terms of mechanisms, octanoic acid inhibits complex I–III in rat liver (Scaini et al., 2012) and excess fumarate may also inhibit complex II activity, although manipulation of fumarate did not alter activity of this complex, suggesting that this is not the case.

We then questioned whether changes in maximal respiration arose from increased biogenesis or from changes in mitochondrial integrity. Our findings suggest that mitochondrial biogenesis was not affected by LPO treatment (Figure 3), because maximal respiration was the only parameter of respiration that changed, and the ratio of nuclear to mitochondrial DNA, as well as HCA microscopy analysis of mitochondrial mass were not altered. In addition, the finding that CS activity was not adversely affected suggests that mitochondrial integrity was not compromised, although this requires further study. These findings are consistent with human studies of NAFLD that show no changes in mitochondrial mass in steatotic liver tissue (Koliaki et al., 2015). In contrast, liver tissue from patients with NASH contains greater numbers of mitochondria and a decrease in maximal respiration, indicating that a transition in mitochondrial function occurs between these two disease states (Koliaki et al., 2015). The reasons for this are unclear; differences in maximal respiration between NAFLD and NASH could reflect impairment of the ETC and/or changes in baseline mitochondrial respiration. In NASH, the decrease in maximal respiration may be a consequence of increased mitochondrial fragmentation and concurrent decreases in




Figure 7. Macrovesicular steatosis in HLCs does not correlate with wide-scale changes in 5hmC enrichment

(A) Correlation heatmap of control versus LPO groups, following hmeDIP sequencing, clustered by Euclidean distance. (B) Proportion of DHRs associated with different regions of the genome, showing the majority located in intragenic and intronic regions. (C) Heatmap of DHRs, with an FDR of <0.05 and k-means clustering. (D) Sliding window analysis of the transcriptional start site (TSS), gene body, and transcriptional end site (TES) shows minimal changes between control and LPO groups. For both control and LPO, $n = 3$ biological replicates/group.

mitophagy (Knott et al., 2008; Koliaki et al., 2015). The differences between studies may also reflect the isolation of mitochondria from the multiple cell types present in whole tissues, which may be altered as a consequence of the disease process. We suggest that the model of hepatic steatosis presented here may mirror the transition between NAFLD and NASH, with respiratory dysfunction in the absence of mitochondrial biogenesis. Future experiments, with longer exposure to LPO and/or the incorporation of non-parenchymal cells into the model, may shed light on this.

In agreement with studies in mouse models, and indirect studies in humans, NAFLD was associated with increased hepatic TCA cycle activity (Figure 5B) (Satapati et al., 2012; Sunny et al., 2011). We identified

substantial disruption of TCA cycle and oxidative phosphorylation pathways indicating compromised energy metabolism in steatotic HLCs. As TCA cycle flux generates NADH and FADH₂, which transfer electrons to the electron transport chain (ETC), alterations in TCA cycling may have a direct impact on respiration and oxidative stress. In order to delineate detailed information on TCA cycle flux dynamics we utilized stable isotopic tracing with ¹³C₃-lactate, which provides greater metabolite labeling than other substrates (Hui et al., 2017). In the liver, flux of substrates into the TCA cycle predominantly occurs via PC (Lardy et al., 1965), and there is evidence suggesting that PC activity increases in NAFLD (Sunny et al., 2011) and contributes to increased rates of gluconeogenesis through conversion of oxaloacetate to phosphoenolpyruvate (Satapati et al., 2012). Our data support the assertion that PC activity increases in steatotic HLCs and that pyruvate is predominantly utilized to sustain TCA cycle activity. Although we observed sustained synthesis of gluconeogenesis-associated metabolites in steatotic HLCs, there was no increase in gluconeogenesis detected (Figure 4). Increased incorporation of only two ¹³C atoms into each of these gluconeogenesis-associated metabolites may suggest that pyruvate-derived acetyl-CoA is being oxidized to OAA via citrate as a means to enter the gluconeogenic pathway.

Although increased flux of substrates into the TCA cycle leads to higher levels of TCA cycle activity (Sunny et al., 2011), our data suggest that changes in the TCA cycle are more nuanced than was previously suggested, with enhanced anaplerosis from pyruvate/lactate into the TCA cycle and inhibition of the conversion of succinate to fumarate in steatotic cells. This raised the question of what leads to the diminished incorporation of ¹³C into succinate. The decreased cataplerosis through glutamate suggests that this could be due to perturbation of TCA cycle equilibrium, leading to altered interconversion of succinyl-CoA and succinate, which may, in turn, lead to the generation of an increased pool of succinyl-CoA. This is supported by the observation of decreases in PC-derived glutamate and succinate, despite no changes in PC-derived α KG. Because interconversion between succinyl-CoA and succinate is in near equilibrium and readily reversible (Lynn and Guynn, 1978), we propose that this effect could be a result of an alteration in the equilibrium of this reaction, with enhanced succinyl-CoA synthesis, which could be elicited through branched-chain amino acid catabolism.

Despite truncation of the TCA cycle, steatotic HLCs rewire their metabolic circuitry to compensate for this, generating increased levels of fumarate through the PNC, and to a lesser extent the MAS. A similar metabolic bypass has been reported in cardiac ischemia (Chouchani et al., 2014), as well as in human and mouse *in vitro* models of tumorigenesis (Tyrakis et al., 2017). In ischemic reperfusion injury, increased PNC activity results in fumarate overflow, driving reversal of succinate dehydrogenase activity and accumulation of succinate (Chouchani et al., 2014). We did not observe the same phenomenon here, but rather found evidence for inhibition of succinate dehydrogenase activity in steatotic HLCs. Although fumarate can be generated from reversal of fumarate hydratase (FH) activity (Chouchani et al., 2014), we were unable to directly manipulate the activity of this enzyme in order to assess its contribution to the fumarate pool in steatotic HLCs. However, as FH operates at equilibrium (Ajalla Aleixo et al., 2019) it is possible that PNC-fueled fumarate accumulation prevents reverse catalytic activity. Defects in complex I can lead to a reduction in the levels of NAD⁺ (Porcelli et al., 2010) and regeneration of fumarate via the PNC may be one mechanism of increasing the NADH pool and maintaining the hydrogen ion gradient of the ETC. Our data suggest that fumarate is important for the development of macrovesicular steatosis; inhibition of the PNC prevented development of macrovesicular lipid droplets, and this was partially restored following the addition of exogenous fumarate (Figure 6K). This correlates with findings in oligodendrocytes and CD8⁺ T cells, in which exposure to exogenous fumarate resulted in perturbed lipid metabolism (Bhargava et al., 2019; Huang et al., 2015), although the mechanism by which this occurs is unknown.

Fumarate accumulation can impact the activity of the α KG-dependent dioxygenase enzyme family, including the ten-eleven translocation (TET) enzymes, which are involved in the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and subsequent steps in the DNA demethylation pathway (Tahiliani et al., 2009). We have previously shown that the TET enzymes play an important role in the development of hepatocellular carcinoma and that 5hmC enrichment is reversibly altered at specific loci in response to hepatic fat accumulation (Lyll et al., 2020; Thomson et al., 2016). 5hmC is a stable epigenetic modification and studies suggest that 5hmC enrichment at transcriptional start sites (TSSs) associates with transcriptional repression (Wu et al., 2011). We did not observe wide-scale changes in 5hmC enrichment, and 5hmC changes at specific loci did not, in general, correlate with transcriptional changes in steatotic cells, except at a limited number of promoter regions.

This human-cell-based model displays many of the transcriptional and metabolic characteristics associated with human hepatic steatosis, and we propose it as a useful addition to the field. Although there are a number of current *in vitro* approaches for the study of steatosis, these often use HCC cell lines, which have perturbed metabolic function arising from the process of malignant transformation and immortalization (Huang et al., 2013; Pavlova and Thompson, 2016). This may limit their utility for studying steatosis-associated metabolic changes in non-malignant cells. Furthermore, culturing of HCC cell lines is associated with loss of 5hmC, making them unsuitable for studying the interplay between mitochondrial metabolism and TET-mediated modulation of the epigenome (Chen et al., 2013; Hernandez-Vargas et al., 2010; Liu et al., 2013; Thomson et al., 2016; Xu et al., 2011). As an alternative, primary mouse and human hepatocytes can be used to model hepatic steatosis, but these cells have a limited lifespan, cannot be passaged or expanded *in vitro*, and human cells are often isolated from fundamentally abnormal, e.g. fatty livers (Hirsova et al., 2016; Lyall et al., 2018). The process of cell sorting may also confound metabolomic, transcriptomic, and epigenomic analyses in cell lines (Llufrio et al., 2018), and the necessity for both tissue disaggregation and cell sorting, which are needed to enable the study downstream effects in individual cell types from whole tissue biopsies, can make the interpretation of results even more challenging (Llufrio et al., 2018). The model system presented here overcomes many of these challenges, as HLCs display a similar metabolic phenotype to human hepatocytes and cell sorting is not required (Wang et al., 2017). Furthermore, these cells retain 5hmC in patterns similar to those observed in humans (Ivanov et al., 2013), making them well suited to studying the interplay between mitochondrial metabolism and the epigenome.

The system, allowing the study of transcriptomic, epigenomic, metabolomic, and proteomic effects in a single cell type, can be adapted for the analysis of effects induced by a variety of alternative agents that may induce steatosis. In addition, this model system can be scaled up to model liver injury (Lucendo-Villarin et al., 2020a; Szkolnicka et al., 2014), genetically modified to study gene function (Wang et al., 2019), and moved into 3D culture for longer-term experimentation (Lucendo-Villarin et al., 2020b). These approaches will be valuable to further determine which genes link metabolic disruption and steatosis and for high-throughput drug screening to identify targets for preclinical analysis.

In conclusion, we propose that steatotic HLCs represent a new and attractive tool to develop a deeper understanding of steatosis-associated biology and for the development of new therapeutics.

Limitations of the study

One limitation of this study is the use of AICAR to block PNC activity and limit fumarate accumulation (Chouchani et al., 2014). AICAR is also an AMP-activated protein kinase (AMPK) agonist (Zhao and Saltiel, 2020). AMPK is a regulator of cellular energy homeostasis, and its activation by Metformin, a commonly used treatment for type 2 diabetes, inhibits gluconeogenesis in the liver (Zhou et al., 2001), which may explain why we did not observe increased activity in this pathway. AICAR may have a number of additional effects, notably through downstream pathways, which make the interpretation of its effects problematic, and further studies exploring the effects of overexpression and/or silencing of metabolic enzymes using siRNA on lipid accumulation and the metabolome will be useful to delineate the precise pathways involved. Similarly, there is some evidence that AOA may exert effects upstream of the MAS, leading to inhibition of gluconeogenesis (Subramanian et al., 2007), supporting the need for additional experiments to dissect the precise effect of this inhibitor in the model presented here. Octanoic acid increases oxidative stress through ROS production (Scaini et al., 2012), so future studies should additionally measure oxidative stress and ROS levels in steatotic HLCs. Further studies are required to determine if the mitochondrial dysfunction is due to defects in individual respiratory complexes or changes in a combination of complexes and whether other aspects of mitochondrial respiration may become compromised with longer LPO exposure. Finally, LPO may induce ER stress (Lockman et al., 2016), which may influence mitochondrial oxygen consumption and contribute to the development of NAFLD (Liu and Green, 2019; Wang et al., 2011).

Resource availability

Lead contact

David C Hay: Center for Regenerative Medicine, University of Edinburgh, Institute for Regeneration and Repair, Edinburgh BioQuarter, 5 Little France Crescent, Edinburgh, EH16 4UU. davehay@talktalk.net.

Materials availability

This study did not generate new unique reagents.

Data and code availability

The accession number for transcriptomic sequencing data reported in this paper is GEO: GSE138052. The accession number for 5hmC sequencing data reported in this paper is GEO: GSE144955. Original raw GC-MS data have been deposited to Mendeley Data: <https://data.mendeley.com/datasets/gd5k5psvf4/1>; <https://doi.org/10.17632/gd5k5psvf4.1>.

METHODS

All methods can be found in the accompanying [Transparent methods supplemental file](#).

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2020.101931>.

ACKNOWLEDGMENTS

MCS was supported by a British Heart Foundation PhD studentship (FS/16/54/32730) and the British Heart Foundation Centre of Research Excellence. SW-Z was funded by the Deutsche Forschungsgemeinschaft (SFB960). This work was supported in part by the Wellcome Trust [grant number 208400/Z/17/Z], and we thank HWB-NMR at the University of Birmingham for providing open access to their Wellcome Trust-funded NMR equipment. RNC and NMM were supported by a Wellcome Trust New Investigator Award to NMM (100981/Z/13/Z). MJL was supported by a Wellcome Trust PhD Fellowship as part of the Edinburgh Clinical Academic Track scheme (102839/Z/13/Z). RRM is supported by the Medical Research Council and by grants from the BBSRC. Research in RRM's lab leading to these results is partly funded by the Innovative Medicine Initiative Joint Undertaking (IMI JU) under grant agreement number 115001 (MARCAR project: URL: <http://www.imi-marc-ar.eu/>). DCH, JMR, and BLV were supported with awards from the MRC Doctoral Training Partnership (MR/K501293/1) and the Chief Scientist Office (TCS/16/37). AJD was funded by the British Heart Foundation Centre of Research Excellence, University of Edinburgh. Our thanks go to the Wellcome Trust Clinical Research Facility Genetics Core, Western General Hospital, Edinburgh, UK. We thank Will Cawthorn for discussions about mitochondrial quantification. Graphical abstract and [Figure 1A](#) were created using the BioRender platform.

AUTHOR CONTRIBUTIONS

MCS was involved in conceptualization, methodology, validation, formal analysis, investigation, data curation, writing (original draft preparation, reviewing, and editing) and visualization. BLV, JMR, MJL, PDW, and AT were involved in methodology, validation, formal analysis, investigation, and writing (reviewing and editing). SW-Z and JPT were involved in software, formal analyses, data curation, and writing (reviewing and editing). RRM, CL, and DAT were involved in conceptualization, methodology, validation, formal analysis, investigation, data curation, provision of resources, writing (reviewing and editing), project administration, funding acquisition, and supervision. DCH and AJD were involved in conceptualization, methodology, validation, formal analysis, provision of resources, writing (reviewing and editing), project administration, funding acquisition, and supervision.

DECLARATION OF INTERESTS

Professor David Hay is a founder, shareholder, and director in Stemnovate Limited. All other authors declare that they have no competing interests.

Received: August 20, 2020

Revised: November 20, 2020

Accepted: December 8, 2020

Published: January 22, 2021

REFERENCES

- Ajalla Aleixo, M.A., Rangel, V.L., Rustiguel, J.K., de Pádua, R.A.P., and Nonato, M.C. (2019). Structural, biochemical and biophysical characterization of recombinant human fumarate hydratase. *FEBS J.* *286*, 1925–1940.
- Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. *Int. J. Exp. Pathol.* *87*, 1–16.
- Asrih, M., and Jornayvaz, F.R. (2015). Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? *Mol. Cell. Endocrinol.* *418*, 55–65.
- Atanasovska, B., Rensen, S.S., van der Sijde, M.R., Marsman, G., Kumar, V., Jonkers, I., Withoff, S., Shiri-Sverdlov, R., Greve, J.W.M., Faber, K.N., et al. (2017). A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. *Hepatology* *66*, 794–808.
- Bhargava, P., Fitzgerald, K.C., Venkata, S.L.V., Smith, M.D., Kornberg, M.D., Mowry, E.M., Haughey, N.J., and Calabresi, P.A. (2019). Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. *Ann. Clin. Transl. Neurol.* *6*, 33–45.
- Boutagy, N.E., Pyne, E., Rogers, G.W., Ali, M., Hulver, M.W., and Frisard, M.I. (2015). Isolation of mitochondria from minimal quantities of mouse skeletal muscle for high throughput microplate respiratory measurements. *J. Vis. Exp.* *2015*, 53217.
- Cazanave, S., Podtelezchnikov, A., Jensen, K., Seneshaw, M., Kumar, D.P., Min, H.K., Santhekadur, P.K., Banini, B., Mauro, A.G., Oseini, A.M., et al. (2017). The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. *Sci. Rep.* *7*, 17193.
- Chen, M.L., Shen, F., Huang, W., Qi, J.H., Wang, Y., Feng, Y.Q., Liu, S.M., and Yuan, B.F. (2013). Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry. *Clin. Chem.* *59*, 824–832.
- Chouchani, E.T., Pell, V.R., Gaude, E., Aksentijević, D., Sundier, S.Y., Robb, E.L., Logan, A., Nadtochiy, S.M., Ord, E.N.J., Smith, A.C., et al. (2014). Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature* *515*, 431–435.
- Collison, K.S., Maqbool, Z., Saleh, S.M., Inglis, A., Makhoul, N.J., Bakheet, R., Al-Johi, M., Al-Rabiah, R., Zaidi, M.Z., and Al-Mohanna, F.A. (2009). Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. *J. Lipid Res.* *50*, 1521–1537.
- Dasika, S.K., Vinnakota, K.C., and Beard, D.A. (2015). Determination of the catalytic mechanism for mitochondrial malate dehydrogenase. *Biophys. J.* *108*, 408–419.
- Fujii, H., Ikura, Y., Arimoto, J., Sugioka, K., Iezzoni, J.C., Park, S.H., Naruko, T., Itabe, H., Kawada, N., Caldwell, S.H., et al. (2009). Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. *J. Atheroscler. Thromb.* *16*, 893–901.
- Gilchrist, E.S., Lockman, K., Pryde, A., Cowan, P., Lee, P., and Plevris, J.N. (2010). PWE-002 Cell growth is impaired in a cellular model of non-alcoholic fatty liver disease, but is unaffected by simple steatosis. *Gut* *59*, A85–A86.
- Hardwick, R.N., Ferreira, D.W., More, V.R., Lake, A.D., Lu, Z., Manautou, J.E., Slitt, A.L., and Cherrington, N.J. (2013). Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver diseases. *Drug Metab. Dispos.* *41*, 554–561.
- Hernandez-Vargas, H., Lambert, M.P., Le Calvez-Kelm, F., Gouysse, G., McKay-Chopin, S., Tavtigian, S.V., Scoazec, J.Y., and Herceg, Z. (2010). Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. *PLoS One* *5*, e9749.
- Hirsova, P., Ibrahim, S.H., Krishnan, A., Verma, V.K., Bronk, S.F., Werneburg, N.W., Charlton, M.R., Shah, V.H., Malhi, H., and Gores, G.J. (2016). Lipid-Induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. *Gastroenterology* *150*, 956–967.
- Huang, H., Taraboletti, A., and Shriver, L.P. (2015). Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. *Redox Biol.* *5*, 169–175.
- Huang, Q., Tan, Y., Yin, P., Ye, G., Gao, P., Lu, X., Wang, H., and Xu, G. (2013). Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. *Cancer Res.* *73*, 4992–5002.
- Hui, S., Ghergurovich, J.M., Morscher, R.J., Jang, C., Teng, X., Lu, W., Esparza, L.A., Reya, T., Zhan, L., Yanxiang Guo, J., et al. (2017). Glucose feeds the TCA cycle via circulating lactate. *Nature* *551*, 115–118.
- Ivanov, M., Kals, M., Kacevska, M., Barragan, I., Kasuga, K., Rane, A., Metspalu, A., Milani, L., and Ingelman-Sundberg, M. (2013). Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. *Genome Biol.* *14*, R83.
- Knott, A.B., Perkins, G., Schwarzenbacher, R., and Bossy-Wetzel, E. (2008). Mitochondrial fragmentation in neurodegeneration. *Nat. Rev. Neurosci.* *9*, 505–518.
- Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W.T., et al. (2015). Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. *Cell Metab* *21*, 739–746.
- Kolwankar, D., Vuppalanchi, R., Ethell, B., Jones, D.R., Wrighton, S.A., Hall, S.D., and Chalasani, N. (2007). Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. *Clin. Gastroenterol. Hepatol.* *5*, 388–393.
- Lardy, H.A., Paetkau, V., and Walter, P. (1965). Paths of carbon in gluconeogenesis and lipogenesis: the role of mitochondria in supplying precursors of phosphoenolpyruvate. *Proc. Natl. Acad. Sci. U. S. A.* *53*, 1410–1415.
- Laursen, T.L., Hagemann, C.A., Wei, C., Kazankov, K., Thomsen, K.L., Knop, F.K., and Grønbaek, H. (2019). Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. *World J. Hepatol.* *11*, 138–249.
- Liu, X., and Green, R.M. (2019). Endoplasmic reticulum stress and liver diseases. *Liver Res.* *3*, 55–64.
- Liu, C., Liu, L., Chen, X., Shen, J., Shan, J., Xu, Y., Yang, Z., Wu, L., Xia, F., Bie, P., et al. (2013). Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. *PLoS One* *8*, e62828.
- Liu, H., Pathak, P., Boehme, S., and Chiang, J.Y.L. (2016). Cholesterol 7 α -hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. *J. Lipid Res.* *57*, 1831–1844.
- Llufrio, E.M., Wang, L., Naser, F.J., and Patti, G.J. (2018). Sorting cells alters their redox state and cellular metabolome. *Redox Biol.* *16*, 381–387.
- Lockman, K.A., Baren, J.P., Pemberton, C.J., Baghdadi, H., Burgess, K.E., Plevris-Papaioannou, N., Lee, P., Howie, F., Beckett, G., Pryde, A., et al. (2012). Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis. *Liver Int.* *32*, 1079–1092.
- Lockman, K.A., Htun, V., Sinha, R., Treskes, P., Nelson, L.J., Martin, S.F., Rogers, S.M., Le Bihan, T., Hayes, P.C., and Plevris, J.N. (2016). Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro. *Lipids Health Dis.* *15*, 114.
- Lucendo-Villarin, B., Nell, P., Hellwig, B., Filis, P., Feuerborn, D., O’Shaughnessy, P.J., Godoy, P., Rahnenführer, J., Hengstler, J.G., Cherianidou, A., et al. (2020a). Genome-wide expression changes induced by bisphenol A, F and S in human stem cell derived hepatocyte-like cells. *EXCLI J.* *19*, 1459–1476.
- Lucendo-Villarin, B., Meseguer-Ripolles, J., Drew, J., Fischer, L., Ma, W.S.E., Flint, O., Simpson, K., Machesky, L., Mountford, J., and Hay, D. (2020b). Development of a cost effective automated platform to produce human liver spheroids for basic and applied research. *Biofabrication* *13*, 015009.
- Lyall, M.J., Cartier, J., Richards, J.A., Cobice, D., Thomson, J.P., Meehan, R.R., Anderton, S.M., and Drake, A.J. (2017). Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD. *Wellcome Open Res.* *2*, 67.
- Lyall, M.J., Cartier, J., Thomson, J.P., Cameron, K., Meseguer-Ripolles, J., O’Duibhir, E., Szkolnicka, D., Villarin, B.L., Wang, Y., Blanco, G.R., et al. (2018). Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. *Philos. Trans. R. Soc. B Biol. Sci.* *373*, 20170362.


- Lyall, M.J., Thomson, J.P., Cartier, J., Ottaviano, R., Kendall, T.J., Meehan, R.R., and Drake, A.J. (2020). Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. *Epigenetics* 15, 61–71.
- Lynn, R., and Guynn, R.W. (1978). Equilibrium constants under physiological conditions for the reactions of succinyl coenzyme A synthetase and the hydrolysis of succinyl coenzyme A to coenzyme A and succinate. *J. Biol. Chem.* 253, 2546–2553.
- Nikolaou, N., Gathercole, L.L., Marchand, L., Althari, S., Dempster, N.J., Green, C.J., van de Bunt, M., McNeil, C., Arvaniti, A., Hughes, B.A., et al. (2019). AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. *Metabolism* 99, 67–80.
- Oligschläger, Y., and Shiri-Sverdlov, R. (2020). NAFLD preclinical models: more than a handful, less of a concern? *Biomedicines* 8, 28.
- Parafati, M., Kirby, R.J., Khorasanizadeh, S., Rastinejad, F., and Malany, S. (2018). A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. *DMM Dis. Model. Mech.* 11, dmm033530.
- Pavlova, N.N., and Thompson, C.B. (2016). The emerging hallmarks of cancer metabolism. *Cell Metab* 23, 27–47.
- Porcelli, A.M., Ghelli, A., Ceccarelli, C., Lang, M., Cenacchi, G., Capristo, M., Pennisi, L.F., Morra, I., Ciccarelli, E., Melcarne, A., et al. (2010). The genetic and metabolic signature of oncogenic transformation implicates HIF1 α destabilization. *Hum. Mol. Genet.* 19, 1019–1032.
- Rector, R.S., Thyfault, J.P., Uptergrove, G.M., Morris, E.M., Naples, S.P., Borengasser, S.J., Mikus, C.R., Laye, M.J., Laughlin, M.H., Booth, F.W., et al. (2010). Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. *J. Hepatol.* 52, 727–736.
- Revill, K., Wang, T., Lachenmayer, A., Kojima, K., Harrington, A., Li, J., Hoshida, Y., Llovet, J.M., and Powers, S. (2013). Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. *Gastroenterology* 145, 1424–1435.e1-25.
- Rinella, M.E., and Green, R.M. (2004). The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. *J. Hepatol.* 40, 47–51.
- Rotundo, L., Persaud, A., Feurdean, M., Ahlawat, S., and Kim, H.S. (2018). The Association of leptin with severity of non-alcoholic fatty liver disease: a population-based study. *Clin. Mol. Hepatol.* 24, 392–401.
- Sahini, N., and Borlak, J. (2016). Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. *Transl. Res.* 177, 41–69.
- Satapati, S., Sunny, N.E., Kucejova, B., Fu, X., He, T.T., Méndez-Lucas, A., Shelton, J.M., Perales, J.C., Browning, J.D., and Burgess, S.C. (2012). Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. *J. Lipid Res.* 53, 1080–1092.
- Satapati, S., Kucejova, B., Duarte, J.A.G., Fletcher, J.A., Reynolds, L., Sunny, N.E., He, T., Arya Nair, L., Livingston, K., Fu, X., et al. (2015). Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. *J. Clin. Invest.* 125, 4447–4462.
- Scaini, G., Simon, K.R., Tonin, A.M., Busanello, E.N.B., Moura, A.P., Ferreira, G.C., Wajner, M., Streck, E.L., and Schuck, P.F. (2012). Toxicity of octanoate and decanoate in rat peripheral tissues: evidence of bioenergetic dysfunction and oxidative damage induction in liver and skeletal muscle. *Mol. Cell. Biochem.* 361, 329–335.
- Schiöth, H.B., Boström, A., Murphy, S.K., Erhart, W., Hampe, J., Moylan, C., and Mwynyi, J. (2016). A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. *BMC Genomics* 17, 462.
- Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakimal, S., and Nair, K.S. (2005). Decline in skeletal muscle mitochondrial function with aging in humans. *Proc. Natl. Acad. Sci. U. S. A.* 102, 5618–5623.
- Subramanian, R.K., Kasumov, T., Yang, L., Cendrowski, A., David, F., Minkler, P.E., Hoppel, C.L., Anderson, V.A., and Brunengraber, H. (2007). Reassessment of the Mechanisms by Which Aminoacetoacetate (AOA) Inhibits Gluconeogenesis (GNG) from Lactate (John Wiley & Sons, Ltd).
- Sunny, N.E., Parks, E.J., Browning, J.D., and Burgess, S.C. (2011). Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. *Cell Metab* 14, 804–810.
- Suppli, M.P., Rigbolt, K.T.G., Veidal, S.S., Heebøl, S., Lykke Eriksen, P., Demant, M., Bagger, J.I., Nielsen, J.C., Oró, D., Thrane, S.W., et al. (2019). Hepatic transcriptome signatures in patients with varying degrees of non-alcoholic fatty liver disease compared to healthy normal-weight individuals. *Am. J. Physiol. Gastrointest. Liver Physiol.* 316, G462–G472.
- Szkolnicka, D., Farnworth, S.L., Lucendo-Villarin, B., Storck, C., Zhou, W., Iredale, J.P., Flint, O., and Hay, D.C. (2014). Accurate prediction of drug-induced liver injury using stem cell-derived populations. *Stem Cells Transl. Med.* 3, 141–148.
- Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* (80-) 324, 930–935.
- Thomson, J.P., Ottaviano, R., Unterberger, E.B., Lempiainen, H., Muller, A., Terranova, R., Illingworth, R.S., Webb, S., Kerr, A.R.W., Lyall, M.J., et al. (2016). Loss of tet1-associated 5-hydroxymethylcytosine is concomitant with aberrant promoter hypermethylation in liver cancer. *Cancer Res.* 76, 3097–3108.
- Tyrakis, P.A., Yurkovich, M.E., Sciacovelli, M., Papachristou, E.K., Bridges, H.R., Gaude, E., Schreiner, A., D'Santos, C., Hirst, J., Hernandez-Fernaund, J., et al. (2017). Fumarate hydratase loss causes combined respiratory chain defects. *Cell Rep* 21, 1036–1047.
- Valenti, L., Bugianesi, E., Pajvani, U., and Targher, G. (2016). Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? *Liver Int.* 36, 1563–1579.
- Wang, L., and Yu, S. (2016). Pathology of non-alcoholic fatty liver disease. *Int. J. Dig. Dis.* 2, 85–89.
- Wang, X., Eno, C.O., Altman, B.J., Zhu, Y., Zhao, G., Olberding, K.E., Rathmell, J.C., and Li, C. (2011). ER stress modulates cellular metabolism. *Biochem. J.* 435, 285–296.
- Wang, Y., Alhaque, S., Cameron, K., Meseguer-Ripolles, J., Lucendo-Villarin, B., Rashidi, H., and Hay, D.C. (2017). Defined and scalable generation of hepatocyte-like cells from human pluripotent stem cells. *J. Vis. Exp.* 55355.
- Wang, Y., Tatham, M.H., Schmidt-Heck, W., Swann, C., Singh-Dolt, K., Meseguer-Ripolles, J., Lucendo-Villarin, B., Kunath, T., Rudd, T.R., Smith, A.J.H., et al. (2019). Multiomics analyses of HNF4 α protein domain function during human pluripotent stem cell differentiation. *iScience* 16, 206–217.
- WHO. (2006). Obesity and Overweight (WHO Media Center), pp. 1–3.
- Wilson, C.H., and Kumar, S. (2018). Caspases in metabolic disease and their therapeutic potential. *Cell Death Differ* 25, 1010–1024.
- Wu, H., D'Alessio, A.C., Ito, S., Wang, Z., Cui, K., Zhao, K., Sun, Y.E., and Zhang, Y. (2011). Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. *Genes Dev.* 25, 679–684.
- Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., Barbera, A.J., Zheng, L., Zhang, H., Huang, S., et al. (2011). Genome-wide Regulation of 5hmC, 5mC, and gene expression by tet1 hydroxylase in mouse embryonic stem cells. *Mol. Cell* 42, 451–464.
- Yamaguchi, M., and Murata, T. (2013). Involvement of regucalcin in lipid metabolism and diabetes. *Metabolism* 62, 1045–1051.
- Zhao, P., and Saltiel, A.R. (2020). From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases. *J. Biol. Chem.* 295, 12279–12289.
- Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. *J. Clin. Invest.* 108, 1167–1174.

Supplemental Information

A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis


Matthew C. Sinton, Jose Meseguer-Ripolles, Baltasar Lucendo-Villarin, Sara Wernig-Zorc, John P. Thomson, Roderick N. Carter, Marcus J. Lyall, Paul D. Walker, Alpesh Thakker, Richard R. Meehan, Gareth G. Lavery, Nicholas M. Morton, Christian Ludwig, Daniel A. Tennant, David C. Hay, and Amanda J. Drake

1




2

3 **Figure S1.** Validation of mRNA sequencing analysis by RT-qPCR. Data were analysed using
 4 two-tailed Student t-test and expressed as mean \pm SD, * $p < 0.05$, **** $p < 0.0001$. Related to
 5 Figure 2.
 6



7


8 **Figure S2.** Representative blot of succinate dehydrogenase subunit A (SDHA) and pyruvate
 9 dehydrogenase (PDH) $\alpha 1$ and $\alpha 2$ subunits, with total protein staining. Molecular weight band
 10 of SDHA = 70 kDa. Molecular weight band of PDh = 38 kDa. Related to Figure 3.
 11



12

13 **Figure S3.** Measurement of mitochondrial (mitochondrial region 2 (MT2); mitochondrial region
 14 3 (MT3)) and nuclear (beta-globin (HBB)) DNA. Data are expressed as mean \pm SD. Related
 15 to Figure 3.

16



17

18 **Figure S4.** Steatotic HLCs show a moderate negative correlation between promoter 5hmC
 19 enrichment and mRNA expression, Related to Figure 7.

20

Gene	Forward sequence	Reverse sequence	Probe
TBP	GAACATCATGGATCAGAACAACA	ATAGGGATTCCGGGAGTCAT	87
NANOG	ATGCCTCACACGGAGACTGT	CAGGGCTGTCCTGAATAAGC	69
ALB	GTGAGGTTGCTCATCGGTTT	GAGCAAAGGCAATCAACACC	7
HNF4A	AGCAACGGACAGATGTGTGA	TCAGACCCTGAGCCACCT	27
PLIN2	TCAGCTCCATTCTACTGTTCCACC	CCTGAATTTTCTGATTGGCACT	72
PLIN4	AGTTCCAAGCCAGGGACAC	TGCTGGGCCTTTTCAATC	1
PLIN5	TACAGTGCAGCCAAGGACAG	CGCACACGCAGTTCTCAG	3
PCK2	CGAAAGCTCCCAAGTACAA	GCTCTCTACTCGTGCCACATC	20
G6PD	AACAGAGTGAGCCCTTCTTCA	GGAGGCTGCATCATCGTACT	5
PLIN2	TCAGCTCCATTCTACTGTTCCACC	CCTGAATTTTCTGATTGGCACT	72
HK1	GACCAAGTTTCTCTCTCAGATCG	CCTAGCTGCTGGAGGATAGC	1
HIF1A	GATAGCAAGACTTTCCTCAGTCG	TGGCTCATATCCCATCAATTC	64

21 **Table S1.** Primer pairs and probes used to quantify mRNA expression, Related to Figure 1
22 and Figure 2.

23

Gene	Forward Primer	Reverse Primer
MT1	CTCACTCTCACTGCCCAAGA	TGAGAATGAGTGTGAGGCGT
MT2	ACCCACCAATCACATGCCTA	GTGTTACATCGCGCCATCAT
HBB	TGGTGCATCTGACTCCTGAG	TCTCCACATGCCAGTTTCT

24 **Table S2.** Primer pairs used to quantify mitochondrial and nuclear DNA, Related to Figure 3.

25

Gene	Forward sequence	Reverse sequence
GAPDH promoter – negative control	CGGCTACTAGCGGTTTTACG	AAGAAGATGCGGCTGACTGT
H19 genic – positive control	GATCTCGGCCCTAGTGTGAA	GTGATGTGTGAGCCTGCACT
UBIAD1 genic – positive control	CTCTTCCTCCTCCTCGTCCT	CATCCAGGAACCACAGTCCT

26 **Table S3.** Primer sequences for validation of DNA immunoprecipitation protocol, Related to

27 Figure 7.

Pathways with upregulated genes		
<i>Pathway</i>	<i>Benjamini</i>	<i>Genes</i>
hsa04713: Circadian entrainment	4.20	ADCY4, ADCY2, CACNA1I, GRIN1, GRIA3, PRKG1, PRKCB, KCNJ5, PLCB4, GRIN2D, CACNA1G, RYR1, GNG2, PER3, GNG4, MTNR1A
hsa04724: Glutamatergic synapse	4.15	ADCY4, DLGAP1, ADCY2, GRIK2, GRIN1, GRIK5, GRIN3B, GRIA3, SHANK1, PRKCB, SLC17A7, GLS2, GRM4, PLCB4, GRIN2D, PLA2G4F, GNG2, GNG4, PLA2G4D
hsa04725: Cholinergic synapse	3.59	ADCY4, ACHE, ADCY2, KCNJ12, KCNJ14, PRKCB, KCNJ4, KCNQ4, KCNQ3, CHRM4, PLCB4, GNG2, PIK3R5, GNG4, KCNQ1, CHRNA3
hsa04750: Inflammatory mediator regulation of TRP channels	3.31	ADCY4, ADCY2, TRPM8, TRPV2, ASIC3, ASIC1, PRKCB, PLCB4, PLA2G4F, PIK3R5, ALOX12, NGF, PLA2G4D
hsa05414: Dilated cardiomyopathy	3.26	ADCY4, ADCY2, ADRB1, SGCG, CACNG8, ITGA8, ITGA7, CACNB1, CACNB4, TNNI3, ITGA2B
hsa04911: Insulin secretion	3.23	TRPM4, ADCY4, ADCY2, PLCB4, KCNN1, KCNN3, ATP1A3, RIMS2, PCLO, KCNJ11, PRKCB
hsa04726: Serotonergic synapse	3.14	GABRB2, PRKCB, KCNJ5, PLCB4, ALOX15B, HTR7, SLC18A2, PLA2G4F, GNG2, HTR1D, HTR3A, GNG4, ALOX12, PLA2G4D
hsa04514: Cell adhesion molecules (CAMs)	2.81	ICAM1, NTNG1, NTNG2, CLDN10, CD40, HLA-DMB, CDH4, HLA-G, NCAM2, ITGA8, NLGN4X, PECAM1, CNTN1, HLA-DOA, CD6, ICOSLG
hsa04921: Oxytocin signalling pathway	2.66	ADCY4, ADCY2, CACNG8, CACNB1, CACNB4, KCNJ12, TRPM2, KCNJ14, PRKCB, KCNJ5, KCNJ4, PLCB4, RYR1, PLA2G4F, NFATC1, PLA2G4D
hsa04080: Neuroactive ligand-receptor interaction	2.43	F2RL2, C5AR1, GABRB2, GRIK2, GRIN1, GABBR1, GRIK5, LPAR3, GRIA3, GRIN3B, P2RX5, GRM4, SSTR2, ADRB1, S1PR1, CHRM4, CHRNA9, SSTR1, GRIN2D, HTR7, CHRNA5, ADRA1A, CALCRL, HTR1D, CHRNA3, GRID1, MTNR1A
hsa04024: cAMP signalling pathway	2.39	ADCY4, HCN2, ADCY2, GRIN1, GABBR1, ATP1A3, GRIN3B, GRIA3, TNNI3, GLI1, SSTR2, ADRB1, SSTR1, PDE4A, GRIN2D, PIK3R5, HTR1D, HCAR2, NFATC1
hsa04020: Calcium signalling pathway	2.37	SLC8A3, ADCY4, SLC8A2, ADCY2, CACNA1I, GRIN1, PRKCB, P2RX5, PLCB4, ADRB1, ATP2A3, GRIN2D, HTR7, CACNA1G, RYR1, ADRA1A, PLCD1
hsa04014: Ras signalling pathway	2.32	FGF19, FGF5, FLT4, FGF17, EFNA3, GRIN1, FGF11, PRKCB, RASAL1, HTR7, RASGRP2, PLA2G4F, PLA1A, GNG2, PIK3R5, NGFR, SYNGAP1, GNG4, RASA4, PLA2G4D, NGF
Pathways with downregulated genes		
<i>Pathway</i>	<i>Benjamini</i>	<i>Genes</i>
hsa05322: Systemic lupus erythematosus	6.65	HIST1H2AB, C7, HIST1H4L, HIST1H2AG, C6, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BM, HIST1H4A, HIST1H2BL, HIST1H2BI, HIST2H2AC, HIST1H2BJ, H2AFX, HIST3H2BB, HIST1H4I, HIST1H4J, HIST2H3A, HIST1H3J, HIST1H2BB, HIST1H2BC,

		HIST1H2BE, HIST1H2BF, HIST1H2BG, HIST1H2BH, ACTN2, HIST2H3C, HIST2H3D, HIST2H2BF, HIST1H3A, HIST1H3B, HIST1H2AI, HIST1H2AH, HIST1H3C, HIST1H3E, HIST1H2AJ, HIST1H3F, HIST1H2AM, HIST1H3G, HIST1H2AL, HIST1H3H, HIST1H3I
hsa00140: Steroid hormone biosynthesis	6.43	HSD3B2, CYP3A4, CYP3A5, CYP3A7, HSD3B1, CYP11A1, HSD17B1, UGT1A9, CYP7A1, UGT2B11, UGT2B4, HSD17B6, UGT2B10, UGT2A3, SULT1E1, UGT2B15, AKR1D1, CYP19A1
hsa00053: Ascorbate and aldarate metabolism	5.37	UGT1A9, UGT2B11, RGN, UGT2B4, UGT2B10, UGT2A3, UGT2B15
hsa04610: Complement and coagulation cascades	5.10	KNG1, F11, PLAT, MBL2, C7, MASP2, F13A1, C6, F9, C4BPB, C4BPA, F13B, F3, KLKB1, SERPINA5, SERPIND1, CPB2
hsa00040: Pentose and glucuronate interconversions	5.02	UGT1A9, KL, AKR1B10, UGT2B11, UGT2B4, UGT2B10, UGT2A3, UGT2B15
hsa05034: Alcoholism	4.92	HIST1H2AB, HIST1H4L, HIST1H2AG, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BM, HIST1H4A, HIST1H2BL, HIST1H2BI, HIST2H2AC, HIST1H2BJ, H2AFX, HIST3H2BB, HIST1H4I, HIST1H4J, HIST2H3A, HIST1H3J, HIST1H2BB, HIST1H2BC, HIST1H2BE, HIST1H2BF, HIST1H2BG, HIST1H2BH, FOSB, HIST2H3C, HIST2H3D, HIST2H2BF, NTRK2, HIST1H3A, HIST1H3B, HIST1H2AI, HIST1H2AH, HIST1H3C, HIST1H3E, HIST1H2AJ, HIST1H3F, HIST1H2AM, HIST1H3G, HIST1H2AL, HIST1H3H, HIST1H3I
hsa00982: Drug metabolism - cytochrome P450	4.88	GSTA1, CYP3A4, GSTA2, CYP3A5, ALDH3B2, ADH1B, ADH1A, FMO5, UGT1A9, FMO1, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15
hsa00830: Retinol metabolism	4.86	CYP3A4, CYP3A5, UGT1A9, CYP3A7, ADH4, UGT2B11, ADH1B, UGT2B4, CYP26A1, HSD17B6, ADH1A, UGT2B10, UGT2A3, UGT2B15, RDH5
hsa05204: Chemical carcinogenesis	4.40	GSTA1, CYP3A4, GSTA2, CYP3A5, CYP3A7, NAT2, ADH1B, ALDH3B2, ADH1A, CYP3A43, UGT1A9, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15
hsa00983: Drug metabolism - other enzymes	4.05	CYP3A4, UGT1A9, NAT2, UGT2B11, UGT2B4, UGT2B10, UGT2A3, UGT2B15, TK1
hsa00980: Metabolism of xenobiotics by cytochrome P450	3.92	GSTA1, CYP3A4, CYP3A5, GSTA2, ALDH3B2, ADH1B, ADH1A, UGT1A9, ADH4, UGT2B11, UGT2B4, UGT2A3, UGT2B10, UGT2B15
hsa04110: Cell cycle	3.01	CDC6, CDK1, PKMYT1, TTK, CDC20, ESPL1, PTTG1, MCM2, CDC25C, CCNB1, CDKN1C, MAD2L1, CCNB2, PLK1, CDKN2C, BUB1, BUB1B, CCNA2
hsa04114: Oocyte meiosis	2.61	CCNB1, CDK1, MAD2L1, CCNB2, PLK1, SGO1, BUB1, FBXO43, PKMYT1, AURKA, ESPL1, CDC20, PTTG1, CDC25C
hsa05202: Transcriptional misregulation in cancer	2.36	PLAT, HIST2H3A, NFKBIZ, HIST1H3J, MMP9, MMP3, HIST2H3C, HIST2H3D, HHEX, EYA1, CDKN2C, HIST1H3A, HIST1H3B, HIST1H3C,

		HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I
--	--	---

28 **Table S4.** Upregulated and downregulated KEGG pathways, Related to Figure 2.

29

<i>Ensembl ID</i>	<i>Gene</i>	<i>Log₂FC</i>	<i>p</i> adj
ENSG00000197444	OGDHL	1.08547769	3.29E-30
ENSG00000166411	IDH3A	0.74709247	7.70E-20
ENSG00000204370	SDHD	0.3777972	0.0003
ENSG00000100412	ACO2	0.26021698	0.002
ENSG00000146701	MDH2	0.23945724	0.0009
ENSG00000073578	SDHA	-0.1593416	0.03
ENSG00000138413	IDH1	-0.1812103	0.03
ENSG00000168291	PDHB	-0.2026402	0.02
ENSG00000131828	PDHA1	-0.2107741	0.01
ENSG00000163541	SUCLG1	-0.2111892	0.006
ENSG00000143252	SDHC	-0.2414483	0.02
ENSG00000150768	DLAT	-0.2619025	0.0003
ENSG00000091483	FH	-0.4936542	1.01E-12
ENSG00000014641	MDH1	-0.5085681	3.36E-13
ENSG00000101365	IDH3B	-0.5405112	5.07E-13
ENSG00000067829	IDH3G	-0.5829934	1.14E-09
ENSG00000100889	PCK2	-0.5852916	3.07E-18
ENSG00000131473	ACLY	-0.6074454	9.80E-24
ENSG00000173599	PC	-0.9409933	3.13E-37
ENSG00000182054	IDH2	-1.0677314	8.52E-45

30 **Table S5.** [Dysregulated genes in the TCA Cycle KEGG pathway], Related to Figure 2.

31

Ensembl ID	Gene	Log₂FC	padj
ENSG00000147614	ATP6V0D2	3.973933876	9.35E-140
ENSG00000198763	ND2	1.473526224	2.53E-06
ENSG00000198888	ND1	1.363322749	6.19E-05
ENSG00000198840	ND3	1.217622162	2.54E-33
ENSG00000212907	ND4L	1.095495883	0.0001
ENSG00000198886	ND4	0.866690501	0.002
ENSG00000114573	ATP6V1A	0.803262336	2.80E-32
ENSG00000198804	COX1	0.656245362	1.17E-09
ENSG00000198899	ATP6	0.634543196	0.009
ENSG00000198938	COX3	0.632275024	2.80E-10
ENSG00000171130	ATP6V0E2	0.589272395	2.52E-11
ENSG00000198727	CYTB	0.557687429	0.02
ENSG00000047249	ATP6V1H	0.506014583	5.94E-13
ENSG00000117410	ATP6V0B	0.479535962	2.58E-11
ENSG00000147416	ATP6V1B2	0.437789019	5.51E-09
ENSG00000128609	NDUFA5	0.381648881	0.0008
ENSG00000204370	SDHD	0.377797199	0.0003
ENSG00000198712	COX2	0.322901415	0.005
ENSG00000073578	SDHA	-0.159341647	0.04
ENSG00000023228	NDUFS1	-0.210017339	0.002
ENSG00000112695	COX7A2	-0.211631763	0.02
ENSG00000156467	UQCRB	-0.2162753	0.03
ENSG00000167792	NDUFV1	-0.222597617	0.007
ENSG00000135390	ATP5MC2	-0.222831627	0.002
ENSG00000143252	SDHC	-0.24144827	0.02
ENSG00000160194	NDUFV3	-0.242343108	0.004
ENSG00000131100	ATP6V1E1	-0.274149444	2.61E-05
ENSG00000189043	NDUFA4	-0.277227615	0.0001
ENSG00000176340	COX8A	-0.278696825	0.001
ENSG00000165264	NDUFB6	-0.28300413	0.005
ENSG00000213619	NDUFS3	-0.29075047	0.001
ENSG00000178741	COX5A	-0.297956503	9.27E-05
ENSG00000110719	TCIRG1	-0.300385483	0.002
ENSG00000090266	NDUFB2	-0.301527793	0.001
ENSG00000174886	NDUFA11	-0.318594422	0.001
ENSG00000169021	UQCRFS1	-0.319382279	2.33E-05
ENSG00000130414	NDUFA10	-0.320916351	3.89E-05
ENSG00000131143	COX4I1	-0.336149045	2.75E-07
ENSG00000158864	NDUFS2	-0.343567449	4.23E-06
ENSG00000139180	NDUFA9	-0.357605693	0.0006
ENSG00000004779	NDUFAB1	-0.360587197	2.52E-05
ENSG00000184076	UQCR10	-0.375287362	3.00E-06
ENSG00000116459	ATP5PB	-0.379803823	9.50E-08
ENSG00000126267	COX6B1	-0.388197692	3.84E-08
ENSG00000100554	ATP6V1D	-0.405728961	7.75E-08
ENSG00000131495	NDUFA2	-0.419069805	1.65E-06
ENSG00000115286	NDUFS7	-0.422028053	0.0002
ENSG00000136888	ATP6V1G1	-0.428892928	2.02E-09
ENSG00000183648	NDUFB1	-0.432392964	0.0003
ENSG00000154518	ATP5MC3	-0.445435152	1.00E-08
ENSG00000125356	NDUFA1	-0.459056555	2.84E-07
ENSG00000179091	CYC1	-0.468189203	1.54E-09

ENSG00000127540	UQCR11	-0.475454692	4.04E-09
ENSG00000110955	ATP5F1B	-0.49393262	1.83E-16
ENSG00000099795	NDUFB7	-0.509075592	1.10E-09
ENSG00000168653	NDUFS5	-0.520875625	8.23E-11
ENSG00000159720	ATP6V0D1	-0.540902137	6.67E-12
ENSG00000147123	NDUFB11	-0.542107011	1.51E-08
ENSG00000178127	NDUFV2	-0.542969651	0.006
ENSG00000124172	ATP5F1E	-0.574462256	1.96E-13
ENSG00000152234	ATP5F1A	-0.606022757	1.10E-17
ENSG00000140990	NDUFB10	-0.613088113	6.15E-12
ENSG00000119013	NDUFB3	-0.65837698	2.66E-11
ENSG00000169020	ATP5ME	-0.663226048	5.18E-18
ENSG00000159199	ATP5MC1	-0.712677613	1.05E-19
ENSG00000241468	ATP5MF	-0.735984185	1.21E-15
ENSG00000099624	ATP5F1D	-0.737422752	3.56E-17
ENSG00000169429	CXCL8	-0.820462236	3.09E-17
ENSG00000164405	UQCRQ	-0.860634282	1.66E-38
ENSG00000198695	ND6	-0.979723775	1.42E-08
ENSG00000143882	ATP6V1C2	-1.543440061	0.005

32 **Table S6.** [Dysregulated genes in the Oxidative Phosphorylation KEGG pathway], Related to

33 Figure 2

34

Ensembl ID	Gene symbol	mRNA expression fold change	5hmC fold change
ENSG00000181418	DDN	3.57	-2.84
ENSG00000105131	EPHX3	2.38	-3.82
ENSG00000086619	ERO1B	1.65	4.05
ENSG00000147408	CSGALNACT1	1.33	3.09
ENSG00000149927	DOC2A	1.26	-2.49
ENSG00000142156	COL6A1	1.24	3.13
ENSG00000137752	CASP1	0.98	2.44
ENSG00000119900	OGFRL1	0.71	2.21
ENSG00000145247	OCIAD2	0.71	3.02
ENSG00000183044	ABAT	-1.26	3.04
ENSG00000144395	CCDC150	-1.50	3.36
ENSG00000167874	TMEM88	-2.02	3.60

Table S7. [Promoter regions of genes with both altered mRNA expression and enrichment of 5hmC], Related to Figure 7.

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Transparent methods

56 **Differentiation of pluripotent human stem cells to hepatocyte-like cells and induction**
57 **of intracellular lipid accumulation**

58 Human female H9 pluripotent stem cells (PSCs) were differentiated to hepatocyte-like cells
59 (HLCs) as previously described (Wang et al., 2017). Unless otherwise stated, compounds for
60 this protocol were purchased from Thermo Fisher. Briefly, H9 cells were cultured on Laminin
61 521 coated plates, with mTeSR1 media, which contained 10 μ M ROCK inhibitor. H9s were
62 initially differentiated to an endoderm phenotype in RPMI 1640 media containing 100 ng/mL
63 Activin A (R & D Systems), and 50 ng/mL Wnt3A (Peprtech). Endodermal cells were then
64 differentiated to a hepatoblast phenotype by culturing in Knockout DMEM, containing 20%
65 Knockout Serum Replacement. Finally, cells were differentiated to a HLC phenotype by
66 culturing in HepatoZYME media containing 10 ng/mL hepatocyte growth factor (Peprtech),
67 20 ng/mL oncostatin M (Peprtech), and 10 μ M hydrocortisone 21-hemisuccinate (Sigma
68 Aldrich), until day 17, at which point the cells were used for the assays described in this
69 manuscript.

70

71 HLCs were cultured in a 96-well format for measurements of lipid accumulation and in a 6-
72 well format for all other analyses. Each well is a separate differentiation event and represents
73 a biological replicate. Intracellular lipid accumulation was induced in HLCs, as previously
74 described (Lyall et al., 2018). Briefly, at day 17, HLCs were incubated in HepatoZYME media
75 only (controls) or HepatoZYME media containing a cocktail of sodium L-lactate (L; 10mM),
76 sodium pyruvate (P; 1 mM) and octanoic acid (O; 2 mM) (Sigma, Gillingham, UK) (LPO) for a
77 period of 48 hours. For isotopic tracing studies, lactate was replaced with $^{13}\text{C}_3$ -lactate (CK
78 Isotopes, CLM-1579-05). For mechanistic studies, HLCs were exposed to either 5-
79 Aminoimidazole-4-carboxamide-1- β -D-ribofuranosyl 5'-monophosphate (AICAR; 1mM;
80 Sigma-Aldrich, A1393-50MG), O-(Carboxymethyl)hydroxylamine hemihydrochloride (AOA;
81 100 μ M ; Sigma-Aldrich, C13408-1G) or AICAR combined with monomethyl fumarate (50 μ M;
82 Sigma-Aldrich, 651419-1G) for the same duration as LPO.

83

84 **Cell mitochondrial stress test assay**

85 The oxygen consumption rate (OCR) of LPO-exposed HLCs was measured using the Agilent
86 Seahorse XF Cell Mito Stress Test Kit (Agilent, 103015-100) on a Seahorse XF Analyser
87 (Agilent, California, USA). Data were collected from two separate plates, with each well
88 representing a biological replicate and each plate representing a technical replicate. Analyses
89 were performed under basal conditions and following treatment with oligomycin A (an ATPase
90 inhibitor), carbonyl-cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP; an ETC uncoupler),
91 and combined rotenone and antimycin A (inhibitors of complex I and III, respectively). Two
92 concentrations of FCCP (0.5 μ M and 1.0 μ M) were used for optimisation. Since replicates
93 within each group responded similarly to each other, results were combined. OCR was
94 normalised to total protein for each well, using the sulforhodamine B (SRB) assay, as
95 previously described (Orellana and Kasinski, 2016), but with spectrophotometric
96 measurements read at 540 nm.

97

98 **Citrate synthase assay**

99 Citrate synthase activity was assessed as a readout of mitochondrial integrity (Boutagy et al.,
100 2015; Short et al., 2005). Mitochondria were isolated using the Mitochondria Isolation Kit for
101 Cultured Cells (Thermo Scientific, 89874), as per the manufacturer's instructions, selecting
102 option A for isolation. Citrate synthase activity, a marker of mitochondrial integrity, was then
103 measured using the Citrate Synthase Activity Colorimetric Assay Kit (BioVision, K318), as per
104 the manufacturer's instructions.

105

106

107

108 **Protein Extraction**

109 Adherent HLCs were washed once with ice-cold PBS, before incubating in ice-cold RIPA Lysis
110 and Extraction Buffer (Thermo Scientific, 89900) supplemented with cOmplete Protease

111 Inhibitor Cocktail tablets (1/10 mL buffer; Roche, 11697498001). The suspended HLCs were
112 placed on ice for 30 minutes, vortexing every 3 minutes, before centrifuging for 20 min at 4
113 °C, 12,000 rpm. The supernatant was collected and stored at -80 °C until needed.

114

115 **Western blot analysis**

116 Protein quantification was performed using the Qubit Protein Assay Kit (Invitrogen, Q33211),
117 as per the manufacturer's instructions. Protein concentration was measured using a Qubit
118 Fluorometer (Invitrogen, Massachusetts, USA). Equal concentrations (50 µg) of HLC protein
119 extract in 4 x Sample Loading Buffer (Li-Cor, 928-40004) were loaded onto NuPAGE 4-12%
120 Bis-Tris Protein Gels (Invitrogen, NP0326BOX). Following resolution, protein was transferred
121 to a methanol-activated polyvinylidene difluoride (PVDF) membrane. Protein transfer was
122 measured using Revert 700 Total Protein Stain Kit (Li-Cor, 926-11010) as per the
123 manufacturer's instructions. To enable probing with different antibodies, membranes were
124 then sliced (images shown in Figure S1), blocked with Tris-buffered saline containing Tween
125 20 (TBST) and 5% skimmed milk powder, and incubated with either Pyruvate Dehydrogenase
126 (staining total α 1 and α 2 subunits) (C54G1) Rabbit mAb (Cell Signaling Technology, 3205) or
127 SDHA (D6J9M) XP Rabbit mAb (Cell Signaling Technology, 11998), both a 1:1000 dilution.
128 The membranes were washed in TBST before incubating with the secondary antibody, IRDye
129 680RD Donkey anti-Mouse IgG (Li-Cor, 926-68072) at a 1:10,000 dilution, for 1 h at room
130 temperature, in the dark, with shaking. Blots were visualised on a Li-Cor Odyssey CLx (Li-Cor,
131 Nebraska, USA), and bands normalised to the Revert 700 Total Protein Stain, as per the
132 manufacturer's instructions.

133

134 **RNA-seq analysis**

135 Total RNA was extracted from HLCs using the Monarch[®] Total RNA Miniprep Kit (New
136 England BioLabs, T2010). RNA integrity was assessed using a Bioanalyzer (Agilent) with the
137 RNA 6000 Nano kit. All samples had a RIN value >7.0. mRNA sequencing was performed on
138 3 biological replicates per group by the Beijing Genomics Institute (BGI) (Shenzhen, China).

139 Library preparation was performed with the TruSeq Stranded mRNA Library Preparation kit
140 (Illumina, RS-122-2101), with additional use of the Ribo-Zero Gold rRNA Removal Kit
141 (Illumina, MRZG12324). Paired-end sequencing was performed on an Illumina HiSeq 4000,
142 with each sample sequenced to a depth >60 million reads. The generated FASTQ files were
143 trimmed to remove adapters, using Trimmomatic (version 0.36) (Bolger et al., 2014), before
144 performing quality control with FastQC (version 0.11.4) (Andrews). Alignment was performed
145 against the *Homo sapiens* GRCh19 assembly. The assembly was first indexed using STAR
146 (version 2.5.1b) before mapping trimmed reads, using STAR (version 2.5.1b) in paired-end
147 mode with default behaviour (Dobin and Gingeras, 2015). Duplicate reads were removed
148 using Picard (version 2.7.11) (2018), before using featureCounts to generate raw read counts
149 for each gene. Differential gene expression (DEG) analysis was performed using DESeq2
150 (Love et al., 2014). Heatmaps were generated with Heatmapper (Babicki et al., 2016).
151 Pathway enrichment analysis was performed using the Kyoto Encyclopedia of Genes and
152 Genomes (KEGG) function (Kanehisa, 2019; Kanehisa and Goto, 2000; Kanehisa et al., 2019)
153 of the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Huang et
154 al., 2009a, 2009b).

155

156 **Real-time quantitative PCR**

157 RNA was taken from that prepared for RNA-sequencing. cDNA was generated using the High
158 Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, 4368814). A master mix was
159 prepared using PerfeCTa FastMix II (Quanta Biosciences, Inc., 95118-250). cDNA was
160 amplified and quantified using the Universal Probe Library (Roche, Burgess Hill, UK) system
161 on a Roche LightCycler 480 (Roche Diagnostics Ltd, Switzerland). Primer sequences and
162 Universal Probe Library probes are detailed in Table S1.

163

164 For quantifying mitochondrial and nuclear DNA, we purified DNA using the Monarch®
165 Genomic DNA Purification Kit (NEB, USA), as per the manufacturer's instructions. DNA was
166 quantified by using the Luna® Universal qPCR Master Mix (NEB, USA) on a Roche

167 LightCycler 480 (Roche Diagnostics Ltd, Switzerland). Primer sequences and Universal Probe
168 Library probes are detailed in Table S2.

169

170 **NMR Spectroscopy**

171 This protocol was previously described by Hollinshead *et al* (Hollinshead et al., 2018). At the
172 conclusion of tracer experiments, cells were washed with 2 mL ice-cold 0.9% saline solution
173 and quenched with 0.3 mL pre-chilled methanol (-20 °C). After adding an equal volume of ice-
174 cold HPLC-grade water containing 1 µg/mL D6-glutaric acid (C/D/N Isotopes Inc), cells were
175 collected with a cell scraper and transferred to tubes containing 0.3 mL of chloroform (-20 °C).
176 The extracts were shaken at 1400 rpm for 20 min at 4 °C and centrifuged at 16,000 x g for 5
177 min at 4 °C. Then, 0.3 mL of the upper aqueous phase was collected and evaporated in
178 eppendorfs, under a vacuum using a Savant™ SpeedVac™ Concentrator (ThermoFisher).
179 These samples were used either for NMR spectroscopy or for GC-MS. For NMR, dried
180 samples were re-suspended in 60 µL of 100 mM sodium phosphate buffer (pH 7.0) containing
181 500 µM DSS and 2 mM Imidazole, 10% D₂O, pH 7.0. Samples were vortexed, sonicated (5-
182 15 min) and centrifuged briefly, before transferred to 1.7 mm NMR tubes using an automated
183 Gilson. One-dimensional (1D)-¹H NMR spectra and two-dimensional (2D)-¹H,¹³C
184 Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) NMR spectra were
185 acquired using a 600 MHz Bruker Avance III spectrometer (Bruker Biospin) with an inverse
186 cryogenic probe for 1.7 mm NMR sample tubes, fitted with a z-axis pulsed field gradient, at
187 300 K. Spectral widths were set to 13 and 160 ppm for the ¹H and ¹³C dimensions, respectively.
188 For the indirect (¹³C) dimension of the 2D-¹H,¹³C HSQC NMR spectra, 1228 out of 4096 (30%)
189 data points were acquired using a non-uniform sampling scheme. ¹³C-¹³C splittings were
190 enhanced 4-fold in the ¹³C dimension. Each sample was automatically tuned, matched and
191 then shimmed (1D-TopShim) to a DSS line width of <1 Hz before acquisition of the first
192 spectrum. Total experiment time was ~15 min per sample for 1D-¹H NMR spectra and 1 h per
193 sample for 2D-¹H,¹³C HSQC NMR spectra. 1D-¹H NMR spectra were processed using the

194 MATLAB-based MetaboLab software (Ludwig and Günther, 2011). All 1D data sets were
195 apodized using a 0.3 Hz exponential window function and zero-filled to 131,072 data points
196 before Fourier Transformation. The chemical shift was calibrated by referencing the DSS
197 signal to 0 ppm. 1D-¹H NMR spectra were manually phase corrected. Baseline correction was
198 achieved using a spline function (Ludwig and Günther, 2011). 1D-¹H-NMR spectra were
199 exported into Bruker format for metabolite identification and concentration determination using
200 Chenomx 7.0 (Chenomx INC). 2D-¹H,¹³C HSQC NMR spectra were reconstructed using
201 compressed sensing in the MDDNMR and NMRpipe software (Delaglio et al., 1995;
202 Kazimierczuk and Orekhov, 2011; Orekhov and Jaravine, 2011). The final spectrum size was
203 922 real data points for the ¹H dimension and 16,384 real data points for the ¹³C dimension.
204 Analysis was performed using MetaboLab and pyGamma software was used in multiplet
205 simulations (Smith et al., 1994). The methyl group of lactate was used to calibrate the chemical
206 shift based on its assignment in the human metabolome database (Wishart et al., 2013).

207

208 **GC-MS**

209 Dried polar metabolites were purified as described for NMR spectroscopy. These were
210 derivatised by incubating with 40 µL 2% methoxyamine hydrochloride (Sigma Aldrich, 226904)
211 in pyridine (Thermo Fisher Scientific, 25104) at 60 °C for 1 h, followed by incubation with 60
212 µL *N*-methyl-*N*-*tert*-butyldimethylsilyltrifluoroacetamide with 1% *tert*-butyldimethylchlorosilane
213 (MTBSTFA with 1% t-BDMCS) at 60 °C for 1 h.

214

215 GC-MS analysis was performed using an Agilent 6890GC in combination with an Agilent
216 5975C MS. The MS was operated under electron impact ionization at 70 eV with the source
217 held at 230 °C and the quadrupole at 150 °C. Helium was used as the carrier gas and
218 maintained at a flow rate of 1 mL/min. 1 µL of derivatised sample was injected (splitless) with
219 an inlet temperature of 280 °C on to a Rxi-5MS column (Restek) The oven temperature was
220 held at 100 °C for 1 min then increased at a rate of 5 °C/min up to a maximum temperature of

221 330 °C. Ions were detected using selected ion monitoring (SIM) mode as previously described
222 (Battello et al., 2016). MetaboliteDetector software was used to correct for the natural isotope
223 distribution and to determine the mass isotopomer distribution (MID) (Hiller et al., 2009).

224

225 **DNA hydroxymethylation immunoprecipitation and sequencing (hmeDIP-sequencing)**

226 DNA was purified using the Monarch[®] Genomic DNA Purification kit (New England BioLabs,
227 T3010S). DNA immunoprecipitation and sequencing was performed as previously described,
228 using the Ion Proton platform (Thomson et al., 2015), with the addition of an IgG control
229 (Merck, 12-370). We validated the DNA immunoprecipitation protocol on Roche LightCycler
230 480 (Roche Diagnostics Ltd, Switzerland), using the primer sets described in Table S3. We
231 sequenced three biological replicates per group. A mean read length of 137-147 base pairs
232 and 21,130,039 - 31,693,844 reads per sample was achieved. Reads were aligned to the hg19
233 genome using Torrent Suite v5.2.0. Aligned reads were sorted using SAMtools, before calling
234 peaks using MACS2 (v. 2.1.1) -f BAM --broad --broad-cutoff 0.05 -B -g hs, over corresponding
235 inputs (Zhang et al., 2008). To detect differentially hydroxymethylated regions (DHRs), we
236 used Diffbind with DESeq2 (Stark and Brown). For Diffbind analysis, data were normalised to
237 a pooled input for each group and an IgG control. DHMRs were assigned to genes and other
238 genomic features using the HOMER (v. 4.8; hg19) annotatePeaks tools (Heinz et al., 2010).
239 For candidate hmeDIP analysis, the concentration of each sample was extrapolated from a
240 standard curve of arbitrary concentrations and normalised to 10% input. Regions of interest
241 were identified from the hmeDIP-sequencing dataset. Primers were designed using the NCBI
242 primer-BLAST software (Table S2). Data are available through the Gene Expression Omnibus
243 (GSE144955). Sliding window profiles and heatmaps were generated using deepTools
244 (Ramírez et al., 2014), using the plotProfile and plotHeatmap functions, respectively, with
245 blacklisted regions subtracted.

246

247 **High content analysis microscopy**

248 Cells were stained with a cell painter assay, adapted from Lyall *et al* and Bray *et al* (Bray et
249 al., 2016; Lyall et al., 2018). Cells were fixed with 50 μ L/well 4% (wt/vol) paraformaldehyde
250 (Electron Microscopy Sciences, 15710-S) for 15 minutes at room temperature. For
251 permeabilisation, cells were incubated in 0.1% Triton X-100 (Sigma-Aldrich, T8787) in PBS
252 for 15 minutes at room temperature. For lipid droplet analysis, cells were then stained with a
253 combination of NucBlue Live ReadyProbes[®] Reagent (2 drops/mL) (Molecular Probes,
254 R37605), HCS CellMask[™] Red (2 μ L/10 mL) (Invitrogen, H32712), and BODIPY[™] 493/503
255 (1:1000) (Life Sciences, D3922), as per the manufacturer's instructions. Following staining,
256 images were acquired using an Operetta High Content Analysis microscope (Perkin Elmer,
257 Buckinghamshire, UK). Lipid droplet morphology was analysed as previously described (Lyall
258 et al., 2018).

259

260 **Statistical analysis**

261 All statistical analyses were performed using Graph Prism Version 8.0 for Windows or macOS,
262 GraphPad Software, La Jolla California USA, www.graphpad.com. Normality of data
263 distribution was measured using the Shapiro-Wilks test. Where indicated, data were analysed
264 by unpaired Student's t-test, Mann-Whitney test, one-way analysis of variance (ANOVA) or
265 two-way ANOVA. Data were considered to be significant where $p < 0.05$.

266

267

268 **References**

- 269 Andrews, S. FastQC: a quality control tool for high throughput sequence data.
- 270 Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., and Wishart, D.S.
- 271 (2016). Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res.* *44*, W147–
- 272 W153.
- 273 Battello, N., Zimmer, A.D., Goebel, C., Dong, X., Behrmann, I., Haan, C., Hiller, K., and
- 274 Wegner, A. (2016). The role of HIF-1 in oncostatin M-dependent metabolic reprogramming
- 275 of hepatic cells. *Cancer Metab.* *4*, 3.
- 276 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina
- 277 sequence data. *Bioinformatics* *30*, 2114–2120.
- 278 Boutagy, N.E., Pyne, E., Rogers, G.W., Ali, M., Hulver, M.W., and Frisard, M.I. (2015).
- 279 Isolation of mitochondria from minimal quantities of mouse skeletal muscle for high
- 280 throughput microplate respiratory measurements. *J. Vis. Exp.* *2015*.
- 281 Bray, M.A., Singh, S., Han, H., Davis, C.T., Borgeson, B., Hartland, C., Kost-Alimova, M.,
- 282 Gustafsdottir, S.M., Gibson, C.C., and Carpenter, A.E. (2016). Cell Painting, a high-content
- 283 image-based assay for morphological profiling using multiplexed fluorescent dyes. *Nat.*
- 284 *Protoc.* *11*, 1757–1774.
- 285 Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995). NMRPipe:
- 286 A multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* *6*,
- 287 277–293.
- 288 Dobin, A., and Gingeras, T.R. (2015). Mapping RNA-seq Reads with STAR. *Curr. Protoc.*
- 289 *Bioinforma.* *51*, 11.14.1-11.14.19.
- 290 Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C.,
- 291 Singh, H., and Glass, C.K. (2010). Simple Combinations of Lineage-Determining
- 292 Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell
- 293 Identities. *Mol. Cell* *38*, 576–589.
- 294 Hiller, K., Hangebrauk, J., Jäger, C., Spura, J., Schreiber, K., and Schomburg, D. (2009).
- 295 Metabolite detector: Comprehensive analysis tool for targeted and nontargeted GC/MS

296 based metabolome analysis. *Anal. Chem.* *81*, 3429–3439.

297 Hollinshead, K.E.R., Munford, H., Eales, K.L., Bardella, C., Li, C., Escribano-Gonzalez, C.,
298 Thakker, A., Nonnenmacher, Y., Kluckova, K., Jeeves, M., et al. (2018). Oncogenic IDH1
299 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance
300 of Mitochondrial Redox Homeostasis. *Cell Rep.* *22*, 3107–3114.

301 Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment tools:
302 Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.*
303 *37*, 1–13.

304 Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative
305 analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* *4*, 44–57.

306 Kanehisa, M. (2019). Toward understanding the origin and evolution of cellular organisms.
307 *Protein Sci.* *28*, 1947–1951.

308 Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes.
309 *Nucleic Acids Res.* *28*, 27–30.

310 Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K., and Tanabe, M. (2019). New approach
311 for understanding genome variations in KEGG. *Nucleic Acids Res.* *47*, D590–D595.

312 Kazimierczuk, K., and Orekhov, V.Y. (2011). Accelerated NMR spectroscopy by using
313 compressed sensing. *Angew. Chemie - Int. Ed.* *50*, 5556–5559.

314 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
315 dispersion for RNA-seq data with DESeq2. *Genome Biol.* *15*, 550.

316 Ludwig, C., and Günther, U.L. (2011). MetaboLab - advanced NMR data processing and
317 analysis for metabolomics. *BMC Bioinformatics* *12*, 366.

318 Lyall, M.J., Cartier, J., Thomson, J.P., Cameron, K., Meseguer-Ripolles, J., O’Duibhir, E.,
319 Szkolnicka, D., Villarin, B.L., Wang, Y., Blanco, G.R., et al. (2018). Modelling non-alcoholic
320 fatty liver disease in human hepatocyte-like cells. *Philos. Trans. R. Soc. B Biol. Sci.* *373*,
321 20170362.

322 Orekhov, V.Y., and Jaravine, V.A. (2011). Analysis of non-uniformly sampled spectra with
323 multi-dimensional decomposition. *Prog. Nucl. Magn. Reson. Spectrosc.* *59*, 271–292.

324 Orellana, E., and Kasinski, A. (2016). Sulforhodamine B (SRB) assay in cell culture to
325 investigate cell proliferation. *Bio-Protocol* 6.

326 Ramírez, F., DüNDAR, F., Diehl, S., Grüning, B.A., and Manke, T. (2014). DeepTools: A
327 flexible platform for exploring deep-sequencing data. *Nucleic Acids Res.* 42, W187-91.

328 Short, K.R., Bigelow, M.L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S., and
329 Nair, K.S. (2005). Decline in skeletal muscle mitochondrial function with aging in humans.
330 *Proc. Natl. Acad. Sci. U. S. A.* 102, 5618–5623.

331 Smith, S.A., Levante, T.O., Meier, B.H., and Ernst, R.R. (1994). Computer Simulations in
332 Magnetic Resonance. An Object-Oriented Programming Approach. *J. Magn. Reson. Ser. A*
333 106, 75–105.

334 Stark, R., and Brown, G. Differential Binding Analysis of ChIP-Seq Peak Data.

335 Thomson, J.P., Fawkes, A., Ottaviano, R., Hunter, J.M., Shukla, R., Mjoseng, H.K., Clark,
336 R., Coutts, A., Murphy, L., and Meehan, R.R. (2015). DNA immunoprecipitation
337 semiconductor sequencing (DIP-SC-seq) as a rapid method to generate genome wide
338 epigenetic signatures. *Sci. Rep.* 5, 9778.

339 Wang, Y., Alhaque, S., Cameron, K., Meseguer-Ripolles, J., Lucendo-Villarin, B., Rashidi,
340 H., and Hay, D.C. (2017). Defined and scalable generation of hepatocyte-like cells from
341 human pluripotent stem cells. *J. Vis. Exp.* e55355–e55355.

342 Wishart, D.S., Jewison, T., Guo, A.C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal,
343 R., Aziat, F., Dong, E., et al. (2013). HMDB 3.0-The Human Metabolome Database in 2013.
344 *Nucleic Acids Res.* 41, D801-7.

345 Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nussbaum,
346 C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq
347 (MACS). *Genome Biol.* 9, R137.

348 (2018). Picard Tools - By Broad Institute.

349